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Abstract

Reduced carotid arterial compliance (CAC) and elevated resting blood pressure
(BP) above the normal (≥120/80 mmHg) increases postmenopausal women’s
cardiovascular disease risk. Isometric handgrip training reduces resting BP across
populations; however its influence on carotid arterial compliance (an independent CVD
risk factor) remains unknown. This study sought to determine the effect of IHG training
on CAC and resting BP in postmenopausal women. CAC and resting BP were measured
in 8 postmenopausal women (65 ± 6 years; mean ± standard deviation) with elevated BP
before and after 8-weeks of IHG training (n=5; baseline systolic BP 138 ± 12 mmHg) or
sham-training (n=3; baseline systolic BP 142 ± 22 mmHg). CAC and resting BP
remained unchanged following the intervention (P > 0.05), however, clinically significant
reductions in resting systolic BP and diastolic BP and were observed. These findings
highlight the use of IHG training as an adjunct therapy for this population, however,
future study is warranted.
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Chapter 1: Introduction and Literature Review
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1.1 Cardiovascular Disease
Cardiovascular disease (CVD) has been identified as the overall leading cause of
death in the world (1). In 2008, CVD-related mortality accounted for approximately 30%
(17.7 million) of the total global deaths, with projections suggesting that by 2030 this
number could reach upwards to 23.6 million deaths per annum (1). CVD places a
significant burden on the Canadian health care system as well (2), where approximately
30% of the overall mortality for the nation in 2009 occurred as a result of CVD-related
complications (3).
It has recently been suggested that CVD is responsible for approximately 40% of
the deaths of Canadian women (4). The relative-risk of developing CVD in these women
has been found to increase four-fold following the transition into menopause (4),
suggesting the importance of directing treatment around this age-determined milestone,
where appropriately timed treatment(s) may be the most effective means in attempting to
manage and/or prevent CVD in this population.
There are a myriad of identified risk factors, yet, approximately 80% of all CVDrelated mortality is associated with arterial dysfunctions and/or disorders (5). These
pathologies can stem from unhealthy lifestyle choices, including excessive alcohol
consumption, habitual tobacco smoking, sedentary lifestyle, unhealthy and/or high
sodium diets, and excessive stress. Sustaining these poor lifestyles can lead to the
development of hypertension (HT) (6), which is considered by the Public Health Agency
of Canada as one of the most important, primary risk factors associated with the
development of CVD (6).

2
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1.1.1 Hypertension
HT is a chronic condition, characterized by elevated arterial blood pressure (BP)
readings that are sustained for a prolonged duration (6). Chronically sustained HT can
result in damage to the vasculature and can produce a number of long-term complications
that increase an individual’s risk for developing clinically significant CVD, which include
stroke, heart failure, peripheral arterial disease, systolic, diastolic heart failure and chronic
renal failure (7-9). HT afflicts over 7.2 million Canadians (6), the majority of whom are
women. By the 6th decade of life, the decade coinciding with menopause (10), the
prevalence of HT in women exceeds that of men (6). Importantly, although HT is
associated with increased rates of all-cause mortality among all Canadian adults ≥ 20
years of age, these rates are 34% higher in females (6).
HT affects all age groups, but the relative risk of establishing this CVD risk-factor
tends to increase as one ages (6). Age-specific prevalence rates are similar across the
sexes for individuals younger than 50. For example, Vasan et al., (11) alarmingly reported
that 90% of the middle-aged and older men and women participating in the Framingham
Heart Study (a longitudinal cohort study), were likely to develop HT over the remaining
years of their life. However, rates for women are increasingly higher than their male
counterparts following the age of 55 and onwards (6). Nevertheless, identifying
individuals who are at an elevated risk of establishing sustained HT and implementing the
appropriate measures to properly manage the progression of the disease early-on can
reduce the risk of developing HT-related complications and CVD (6). Furthermore,
elevations in systolic blood pressure (SBP) by an increment of 20 mmHg or diastolic
blood pressure (DBP) by an increment of 10 mmHg within the range of 115/75mmHg to

3
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185/115 mmHg doubles the risk of CVD for individuals between the ages of 40 and 70
years (9). Therefore, implementing a HT-management plan that can facilitate modest
decrements in resting BP in those who have been diagnosed with, or are at risk for the
development of HT can reduce the risk of acquiring severe, cardiovascular-related
complications, such as heart and renal failure, stroke and others (6;12).

1.1.2 Arterial Blood Pressure
Arterial BP is described as the force that the blood exerts on the arterial walls
during its transit through the cardiovascular system (CVS) (6). Arterial BP is commonly
described by two numbers, systolic and diastolic blood pressure. SBP is the pressure that
the blood exerts on the arterial walls during the contraction phase of the cardiac cycle,
coinciding with peak systole, whereas DBP is the pressure that the blood exerts on the
arterial walls during the relaxation phase of the cardiac cycle, coinciding with diastole (6).
Mean Arterial Pressure
Mean arterial pressure (MAP) describes the average BP within the CVS of an
individual (13). The MAP is slightly lower than the simple arithmetic average of SBP and
DBP, due to the relative time spent during systole and diastole throughout the cardiac
cycle. Systole (ventricular contraction) encompasses 1/3rd of the cardiac cycle, while
diastole (ventricular relaxation) spans the remaining 2/3rd (13). Because of this transitional
relationship between systole and diastole through the cardiac cycle, MAP is thusly
determined by the following equation: MAP = 1/3(SBP) + 2/3(DBP) (13).
MAP is also represented as the product of the haemodynamic, mathematical
relationship between cardiac output (Q) and total peripheral resistance (TPR), which is
expressed by the following equation: MAP = Q x TPR (13).
4
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The interplay between modifications to either Q or TPR will produce changes to
MAP, ultimately resulting in either an elevation or a reduction of arterial BP, where
increases in Q, TPR or both will provide the appropriate stimulus to elevate BP (13).
Cardiac Output
Q represents the rate of arterial blood flow per minute that occurs as a result of
cardiac contraction and the subsequent ejection of blood from the ventricles into the
peripheral vasculature (13). Q is the product of heart rate (HR) and stroke volume (SV),
and is expressed as millilitres of blood pumped per minute: Q = HR x SV (14). Q can also
be derived through the rearrangement of the mathematical relationship between MAP and
TPR, where: Q = MAP/TPR (14).
Total Peripheral Resistance
TPR describes the sum of the resistance exhibited by the vasoconstriction or
vasodilation of the resistance arterioles of the peripheral vasculature throughout the
systemic circulation (13). The tonic state of the vasculature is dependent upon the
contractile state of the vascular smooth muscle cells (VSMC) that surround the arteries
and veins. In order to initiate VSMC contraction, an action potential travels across the
VSMC membrane which stimulates the opening of a voltage-gated calcium ion (Ca2+)
channel. This allows Ca2+ to flux into the cell, thereby increasing intracellular Ca2+
concentrations and stimulates the release of stored Ca2+ from the sarcoplasmic reticulum
(14;15)

. The elevated levels of intracellular Ca2+ become sufficient to activate the Ca2+-

binding protein calmodulin, which subsequently binds to and activates myosin kinase.
The activated myosin kinase phosphorylates myosin, thereby increasing the binding
affinity of actin for myosin and stimulates VSMC contraction (14;15) (Figure 1; page 111).
5
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TPR is estimated using the mathematical relationship between TPR, Q and MAP
(TPR = MAP/Q). This relationship is a physiological representation of the physical laws
governing flow, pressure and resistance that are used to describe laminar flow through a
tube, Poiseuille’s Law: ΔP = 8µLQ/πr4 (15). A simple rearrangement of the formula
suggests that any elevations in either TPR or Q would be sufficient to drive elevations in
MAP.
TPR is influenced by a number of autonomic (sympathetic (SNS) and
parasympathetic (PNS) nervous systems) and neurohumoral mechanisms [i.e.,
norepinepherine (NE), epinephrine (E), acetylcholine (ACh), and nitric oxide (NO),
prostacyclin, adenosine, and endothelin-1 (ET1)], and will be elevated or reduced based
on the interplay between these mechanisms and their relative influence on the vascular
smooth muscle within the CVS.

1.1.2.1 Neural Control of Arterial Blood Pressure
Central Command and the Cardiovascular Control Centre
The neural influence on our CVS at the onset of, and during the participation in
exercise is largely regulated by a central neural mechanism, known as the “central
command center”, or CC (16) (Figure 2; page 112). During periods of physiological
stress, the CC innervates the cardiovascular control center (CCC; i.e. the medulla) via
efferents to modify the activity of the autonomic nervous system (ANS) (14). The ANS is
separated into two functionally distinct branches, the SNS and the PNS. The SNS has a
stimulatory effect on the CVS (increases HR, SV, and TPR), while the PNS has a
quiescent effect on the body, ultimately acting to reduce HR, SV and TPR (14). Both
branches of the ANS work synchronously, where the elevation or reduction of one system
6
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with respect to the other produces a physiological response. The SNS often acts in a
“mass discharge” fashion, where all the portions of the SNS are activated simultaneously
as a complete unit, while elevations of the PNS are usually the response to a specific
localized stimulus (14).
Although CC and its association with changes in cardiovascular physiology
commonly implies an effort-induced modulation of autonomic function, it has been noted
that the cerebral cortical regions involved in the central cardiovascular command do not
always require the parallel activation of central motor command systems to exert their
influence. The magnitude of the CC-mediated CV-response during exercise can be
independent of force production (eg. imagined exercise) and is mostly dictated by an
individual’s perception of effort (17), a process that occurs even at the onset of exercise.
A ‘feed-forward’ mechanisms has been implicated in the preparation of the CVS
at the onset or in an immediate response to exercise (14), however, it has been suggested
that there would not be sufficient time for this feedback mechanism to be sent from the
active peripheral muscles to innervate CV control within the brainstem (17). It has been
postulated that an individual’s perception of the upcoming exercise bout could act as the
feedback mechanism to establish the magnitude of the CC response to the exercise (17).
Primary regions within the cerebral cortex have been found to be associated with
modulations in autonomic function in response to handgrip exercise and other stimuli,
including the insular cortex and the anterior cingulate cortex (18) and the medial prefrontal
cortex (18-20).
The insular cortex has efferent pathways into several well-recognized
cardiovascular control regions (eg., the lateral hypothalamus, rostral ventrolateral medulla
7
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and the nucleus of the solitary tract) and is able to modify both HR and BP upon
activation (21). The insular cortex and anterior cingulate cortex are both activated during
static handgrip exercise by the CC independent of the muscle metaboreflex or elevations
in BP (18), suggesting that brief HG activates the right posterior insular region during but
not immediately post-exercise, and that this activation covaries with changes in BP in
response to the exercise (19).
The thalamus is also intimately involved with the cardiovascular response
physiological stimuli, as the activation of the inferior regions of the thalamus (right and
left inferior thalamic regions; analogous to ventroposterior regions that have been
previously demonstrated to share connections with the insular cortex) have been found to
occur in response to handgrip exercise in humans (19). The thalamus monitors and
controls cardiovascular responses, as changes in both BP and HR also influence thalamic
activity (a large portion of the carotid baroreceptor-related neurons from the ventrocausal
nucleus of the thalamus are involved with the integration of afferent baroreceptor
information (22), and the direct stimulation of these thalamic regions can result in increases
in HR and BP in humans (23).
The insular cortex and anterior cingulate cortex may work in concert as a CC
network that functions to interpret an individual’s sense of effort and then facilitate the
appropriate autonomic adjustments to prepare them for the upcoming physiological stress.
The thalamic regions have a key role in the overall regulation of BP via baroreflex
mechanisms and likely play a role in CC-induced changes in baroreflex function in
response to exercise. To further this notion, recent work using a tendon vibration model
to alter CC input (24) found that the resetting of the carotid baroreceptor stimulus response
8
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curve during exercise could be modified by selectively altering the CC activation. This
work solidifies CC’s involvement in the carotid baroreceptor resetting during exercise
(25;26)

and suggests that exercises producing long-term modifications to CC outflow or

input could result in an exercise-induced carotid baroreceptor sensitivity resetting and
subsequently reduce BP (24). This phenomenon is important to note with respect to
individuals with elevated resting BP performing isometric exercises, as previous work has
demonstrated that increased BP is associated with alterations in baroreceptor reflex
function (27;28) and that repeated performance of isometric exercise contributes to the
resetting of the baroreceptors and reductions in BP (29).
The CCC monitors arterial BP and modifies the ANS in order to maintain optimal
levels of blood perfusion to essential organs during activities of daily living. Not only
does the CCC receive feed-forward information regarding the onset of stress from the CC,
its response to a stimulus is also influenced via afferent signals sent from specific sensory
receptors located within the periphery (14). These receptors are in place to monitor and
respond to the physiological status of the peripheral circulation, and modify the ANS in
response to locally produced stimuli. These receptors include the arterial baroreceptors,
peripheral chemoreceptors and muscle afferent receptors (14).
Arterial Baroreceptors
Arterial BP is regulated and monitored in the CVS via the arterial baroreceptors
(14)

. The arterial baroreceptors are located within the walls of the carotid artery, within

the carotid sinus, and the wall of the aortic arch (14;30). These specialized receptors do not
directly monitor arterial BP, but rather, are influenced when pressure differences in the
arterial circulation result in conformational changes to the receptor. These
9
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conformational changes occur as a result of reduced stretch of the receptor in response to
modified arterial BP, and in turn, innervate the ANS via afferents sent to the CCC (14;30).
The CCC is responsible for integrating the received information from the arterial
baroreceptors with the originally initiated response to the current physiological demands,
ultimately resulting in adjustments to the ANS to maintain cardiovascular homeostasis
(14;30)

.

Peripheral Chemoreceptors
Peripheral chemoreceptors are specialized sensory receptors that detect reductions
in the oxygen saturation (31), and modifications to carbon dioxide (CO2) and/or hydrogen
ion (H+) concentrations (14) of the arterial blood. These chemoreceptors are also located
within the carotid and aortic bodies, monitoring the chemical composition of the blood as
it leaves the heart and enters the peripheral circulation (14;31). When a shift from
homeostasis is detected, the chemoreceptors send modified signals via afferents to the
CCC, which in turn, integrates this information and modifies the influence of the ANS
(mainly the SNS) to increase vascular tone and arterial BP in an attempt to maintain
adequate perfusion to essential organs while removing metabolic byproducts like CO2 and
H+ (14).
Muscle Sensory Receptors
Muscle sensory receptors have an important influence on BP regulation during
periods of brief or prolonged exercise (32;33). There are two main sensory receptors within
the muscles: i) mechanoreceptors, which detect the mechanical compression or stretching
based on the movements of the tissues adjacent to the receptor and ii) metaboreceptors,
which detect the metabolic changes within the tissue that occur in response to a specific
10
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action or stimuli (33;34). These sensory receptors work in concert, monitoring and
influencing the local environment of the working muscle by sending afferent signals
concerning the relative work of the tissue to the CCC to modulate the ANS control of
arterial BP (34) in response to the demands of the activity.
The neural regulation of arterial BP involves the integration of a plethora of
information formed within specific regions of the brain and that sent from peripheral
sensory receptor afferents, all of which influence the CCC to initiate modifications in the
control of arterial BP when attempting to maintain homeostasis within the CVS during
periods of physiological stress.

1.1.2.2 Local Control of Arterial Blood Pressure
The local control of arterial BP involves the release and/or production of
vasoactive compounds from sites within the CVS, their subsequent influence on the tonic
state of the vascular smooth muscle that surrounds the resistance arterioles, and the
resultant alterations in blood flow that occurs in response to the metabolic requirements
of a specific tissue or muscle (35). These vasoactive compounds therefore have the ability
to directly modify arterial BP (14). The most prominent locally produced substances that
initiate vasodilation include potassium (35), NO (14;36), adenosine and the adenine
nucleotides (14;35;37), while ET1 (38), prostacyclin and in special circumstances adenosine as
well (via the A3 receptor within the peripheral vasculature and inflammatory respiratory
disorders (39;40)) are potent vasoconstrictors.

1.1.2.3 Hormonal Control of Blood Pressure
A large number of hormones are intimately involved with the regulation of arterial
11
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BP, including catecholamines (released from the PNS, SNS and adrenal medulla), renin
(released from the juxtaglomerular cells of the kidneys), aldosterone (released from the
adrenal cortex), vasopressin (released by the pituitary gland), and atrial natriuretic peptide
(ANP; released by the heart) (14). All of these hormones work in concert with the local
and neural control mechanisms to maintain arterial BP homeostasis.
Norepinephrine
The SNS neurons that act upon peripheral vascular beds release the catecholamine
neurotransmitter NE, which activates the α1-adrenergic receptors within the vascular
smooth muscle to initiate vasoconstriction (41) (Figure 3; page 113). During this process,
excess NE is released from the synapse in order to ensure a contraction within the target
tissue. In order to ensure regulated functioning, α2-adrenergic receptors are located
within the nerve terminal on the pre-synaptic neuron that monitor synaptic concentrations
of NE and, when activated, have the ability to inhibit any further NE release (14;42).
Epinephrine
E is recognized by both the α and ß-adrenergic receptors (14;42). At the level of the
heart, E acts upon the ß-adrenergic receptors to enhance the sympathetic influence on
cardiac function, increasing the contractile force and the speed of each cardiac
contraction, thusly increasing HR and thereby increasing arterial BP (14;36;42).
E also affects the vasculature in one of two ways; the activation of the αadrenergic receptors result in vasoconstriction in a similar manner as NE (increasing TPR
and arterial BP), while E’s interaction with the vascular ß-adrenergic receptors induces
vasodilation by modifying intracellular Ca2+ concentrations (14;36;43) (Figure 4; page 114).
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Acetylcholine
ACh is released as the neurotransmitter of the PNS and is able to influence
peripheral vascular tone by stimulating vasodilation within the vasculature of the sacral
and cranial regions of the body through the activation of the muscarinic type III receptors
(14;36;44)

(Figure 5; page 115), however, this process contributes minimally to reductions

in BP (45).
Within the heart, ACh is involved with the regulation of cardiac contractility and
heart rate. The interaction of ACh with the muscarinic receptors of the myocardium
results in a reduction in cardiac contractility and diastolic filling (14;36), while HR can be
directly reduced via vagal innervation at the sinoatrial and atrioventricular nodes (14;36;44).
These spontaneously depolarizing groups of cells control the rate that an action potential
spreads through the myocardium to initiate each cardiac contraction, however, vagal
innervation hyperpolarizes these regions and effectively slows the rate of depolarization
within the tissue, slowing HR, reducing Q and decreasing arterial BP (14;36;44).
The Renin-Angiotensin-Aldosterone System
The kidneys have been widely recognized as an essential organ involved with
arterial BP regulation by controlling total blood volume through urinary excretion and
acting as an endocrine organ to produce hormones that modulate vascular tone. The
primary endocrine functions of the kidneys are mediated through the renin-angiotensinaldosterone system (RAAS) (14;36) (Figure 6; page 116). The majority of the RAAS
involvement in BP regulation is accomplished through the activation of the potent
vasoconstrictor angiotensin II (ANG II) in response to various stimuli including reduced
BP, blood volume, elevated dietary sodium consumption, SNS innervation (14;36) and its
13
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interaction with its receptors within the vascular smooth muscle (Figure 7; page 117).
Angiotensin II also acts at the level of the kidneys to elevate fluid and sodium retention in
attempts to elevate blood volume and BP (14;36). ANG II furthers its function by
stimulating the release of aldosterone from the adrenal cortex, which acts at the kidney to
promote sodium retention in order to increase blood volume and arterial BP (14;46).
Lastly, ANG II is an important regulatory hormone for thirst (47), where arterial
baroreceptor-mediated elevation in fluid intake results in an increase in total blood
volume, which subsequently elevates arterial BP (47). When BP maintained, ANG II
production is attenuated and the potentiation of thirst is inhibited, thereby reducing the
endocrine-driven fluid intake and any further increases in total fluid volume (14;47).
Vasopressin
Vasopressin (a.k.a. anti-diuretic hormone or ADH) is a peptide hormone that is
produced within the hypothalamus and secreted from the posterior pituitary in response to
reductions in arterial BP (14). Vasopressin has two specific roles in BP regulation, i)
acting as a vasoconstrictor to elevated BP upon activation of the vasopressin type I
receptor within the vascular smooth muscle (Figure 8; page 118), and ii) promoting fluid
retention via vasopressin type II receptor-mediated insertion of aquaporin 2 within the
distal convoluted tubules and collecting ducts of the kidneys (14;46)
Atrial Natriuretic Peptide
When met with increased BP, the atria respond through the release of a locally
produced peptide hormone, ANP. ANP acts to reduce BP in several ways, either by i)
initiating vasodilation within the peripheral vasculature (54), ii) reducing aldosterone
excretion from the adrenal cortex (14;48), iii) acting as an aldosterone antagonist to
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stimulate sodium excretion at the level of the kidneys (14), or iv) quieting SNS vascular
innervation (14;48;49) (Figure 9; page 119).

1.1.2.4 Genetic Basis for Arterial Blood Pressure Regulation
A large number of receptors and proteins are involved with the regulation of
arterial BP. As such, several genetic polymorphisms involving these proteins have been
identified to be associated with elevated resting BP – including those located on
chromosome 17q12-21, the 122 cM region of chromosome 15 (50), and the 70 cM region
of chromosome 7 (51). Although these regions are suspected to house BP regulatory
genes, the specific gene candidates located within them remain to be identified (51).

1.1.2.5 Effects of Anxiety on Arterial Blood Pressure
Elevations in BP have been found to occur in situations of excessive stress and/or
anxiety as a consequence of elevated SNS activity induced by the emotional state (52). An
individual’s habitual level of anxiety has been found as a definitive link between
environmental stress and the cardiovascular responses that may mediate the establishment
of, and contribute to sustained elevations in BP (53). Other emotional states (i.e. happiness
or anger) also possess the potential to significantly elevate BP measurements in both
healthy (54) and clinical populations (55), where the intensity of happiness has been found
to be inversely related to SBP, while the degree of anxiety was positively correlated with
DBP (56). Furthermore, anxiety and depression are associated with established HT, where
the physiological effects of these mental states contribute to the relative degree of BP
elevation in these individuals (57). The emotionally-mediated elevation in BP occurs as a
result of SNS activation during periods of perceived un-comfort or distress, resulting in a
catecholamine-mediated elevation in vascular tone and HR and contributes to elevated
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arterial BP, HT, and CVD in these individuals (58).
In order to account for the potential impact that variations in the acute and chronic
stress levels may have on cardiovascular measurements, questionnaires such as the StateTrait Anxiety Inventory (STAI) have been developed. This questionnaire allows for a
tangible, daily and self-reported anxiety score that can represent the potential impact of
emotional stress on BP regulation (59). The STAI consists of two, 20-item scales, which
are used for measuring the intensity of anxiety as an emotional state (STAI-S) and the
individual differences in anxiety proneness as a personality trait (STAI-T) (56). Anxiety
levels assessed by the STAI have been identified as a psychological factor that holds an
independent predictive value for changes in BP and HR as a result of the emotional status
of pre-HT (60) and HT individuals (61).

1.1.3 Methods for Measuring Arterial Blood Pressure
The determination of resting BP has been historically used to stratify an
individuals’ relative risk for HT-related CVD. Values for resting BP can be obtained
through a variety of techniques, both invasive and non-invasive. More recently,
ambulatory techniques have been developed to allow arterial BP monitoring over a
consecutive 24-hour period in an attempt to account for an individual’s diurnal BP
variations, and use this variability to construct a more accurate MAP measurement for
individuals with suspected HT.

1.1.3.1 Invasive Blood Pressure Measurement
Invasive BP measurements involve the direct measurement of arterial pressure via
the insertion of an intravascular cannula (hollow needle) into a peripheral artery, most
commonly the radial, femoral or brachial artery (62). The cannula is connected to a
16
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pressure-transducer, allowing the observer to monitor the patients BP on a beat-by-beat
basis (62). The invasive nature of this technique provides a myriad of risks, including
thrombosis, increased risk of infection and bleeding at the insertion site (62). The
possibility of experiencing an adverse event during invasive BP measurements has
resulted in the reservation of this technique solely for intensive-care situations primarily
housed in clinical settings (62).

1.1.3.2 Non-Invasive Blood Pressure Measurement
Non-invasive BP measurement techniques include i) stethoscope auscultation with
sphygmomanometry, ii) automated oscillometry, iii) 24-hour ambulatory BP (ABP), iv)
ultrasonography, v) the Peñáz/Wesseling-method (Finapres/Portapres), and vi) arterial
tonometry.
Sphygmomanometry and Auscultation
Sphygmomanometric auscultation has been considered the “gold-standard” noninvasive method for the determination of arterial BP. When sphygmomanometry is
performed, an appropriate sized cuff is selected for each patient and is fitted snuggly
around the upper arm, oriented around the brachial artery at the elbow (63). The cuff is
manually inflated until the artery is completely occluded (63;64). During auscultation of the
brachial artery with a stethoscope, the examiner manually releases pressure from the cuff.
When the pressure drops to a value below systolic arterial pressure, the 1st Korotkoff
sound is heard as the blood begins to once again flow through the previously occluded
artery. The cuff pressure that allows for the 1st Korotkoff sound to be heard by the
examiner is representative of SBP (63;64), while the pressure that allows for the 5th
Korotkoff sounds to be heard represents DBP (63;64).
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Although this technique continues to provide the most accurate measures of
arterial BP, several limitations do exist. Firstly, the auditory assessment of Korotkoff
sounds tend to give values for SBP that are lower and DBP that are higher than the true
intra-arterial pressure, where some differences have been found to be as large as 25
millimetres of mercury (mmHg) between the two methods (63). Secondly, this technique
is not appropriate in situations where the disappearance of sounds cannot reliably be
determined, whether it is difficult to discern between each Korotkoff phase, or when
sounds are still audible following the complete deflation of the cuff (63). Finally, when
measuring resting BP using this technique with older patients who display wide pulse
pressure (PP; the difference between SBP and DBP, where PP = SBP - DBP), the
auscultatory gap phenomenon must be considered. This occurs when the Korotkoff
sounds become imperceptible between systolic and diastolic pressure, but reappear as cuff
deflation is continued (63;64). The auscultatory gap phenomenon can be eliminated by
elevating the arm overhead for 30 seconds before inflating the cuff, then returning the
arm back to the standard position to continue the measurement (63). This simple technique
reduces the vascular volume in the measured limb and promotes greater inflow to
enhance the Korotkoff sounds (63).
Automated Oscillometry
Automated oscillometry is based upon the observation of the oscillations in blood
flow that are produced during the cardiac cycle (64). The process involves the use of a
sphygmomanometric cuff that is programmed to automatically inflate and deflate while
the oscillations in pressures are monitored via an electronic pressure sensor (64). The cuff
is initially inflated to a pressure that exceeds systolic arterial pressure, and is gradually
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reduced over a 30 second period to a pressure that falls below diastolic pressure. The
electronic pressure sensor automatically interprets the raw data and reports SBP and DBP
following an algorithm-based computation (64).
The main advantage of this technique is that no transducer needs to be placed over
the measured artery, therefore, accurate cuff orientation is not critical (63;64). Furthermore,
this method is less susceptible to external noise (but not to low-frequency mechanical
vibrations), can be used for ABP measurements, and eliminates any potential
inconsistencies with respect to the hearing ability or the level of skill of the possessed by
the examiner (63;64). However, the glaring limitation of this technique is that the amplitude
of the oscillations depends on several factors other than BP, most specifically the arterial
stiffness (63). Therefore, certain populations (i.e. the elderly) who display elevated arterial
stiffness and wide PP may have their true MAP significantly underestimated (63).
Secondly, the algorithms used by the monitors to detect SBP and DBP are different
between models and are not divulged by their manufacturers, a problem that is most
concerning when comparing measurements taken using different devices that commonly
produce significant differences between readings (63). Finally, the bladders deflate at a
manufacturer-determined “bleed-rate”, which assumes a regular pulse between bleed
steps as part of the algorithms used to determine BP (63), and hence, any subtle changes in
cardiac performance during the measurement could skew the reported values. Although
automated oscillometry has been traditionally used to measure resting BP, recent
modifications have also allowed for this technique to be employed while individuals are
mobile, reflecting their 24-hour ABP.
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24-Hour Ambulatory Blood Pressure
ABP monitoring is a fully automated technique where arterial BP is recorded over
an extended period of time (typically 24-hours) while individuals perform activities of
daily living (63;64). This technique has been used for decades in the research setting and
has recently gained popularity as an important prognostic index for CVD-related
morbidity and mortality (65;66), where ABP assessments have been found to be more
accurate in identifying those at elevated CVD-risk when compared to traditional resting
BP measures (67). ABP monitoring can provide information about three clinically
significant measures of arterial BP, i) the overall daily average, ii) the diurnal variation,
and iii) the short-term variability (64). The standard equipment used for ABP monitoring
includes a small automated oscillometric device coupled with an appropriate sized cuff,
which is then attached to a belt and fixed to the participants arm around the brachial
artery, respectively (63). During a standard ABP monitoring session, arterial BP is
measured from the non-dominant arm every 15 or 30 minutes over a 24-hour period,
preferably on a work day (63). After the 24-hour period, the total number of readings
(reaching between 40 and 100) are downloaded into device-specific computer software,
where the raw data is synthesized into a report that provides mean values for MAP, SBP,
DBP, PP, and HR by hour and period: daytime (awake), nighttime (asleep), and a 24hour overall summary (63).
Despite the convenience of ABP monitoring, several limitations do exist. The
device should be calibrated through a series of comparisons with arterial BP determined
via mercury sphygmomanometry to ensure that the device is giving accurate readings
(within 5 mmHg from the mercury readings) (63). Furthermore, it is important to instruct
the patient to hold their arm still at their side while the device is taking readings in order
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to obtain the most accurate BP measures (63). Finally, in order to account to individual
variations in circadian rhythm, it might be helpful to ask patients to record a diary of
activities, particularly with respect to when going to bed and when awaking in the
morning (63).
Ultrasonography
The use of ultrasonography for BP determination incorporates the use of an
ultrasound transmitter placed directly over the brachial artery, underneath a
sphygmomanometric cuff (64). The cuff is inflated until blood flow through the brachial
artery is occluded. Upon deflation, the movement of the arterial wall at peak SBP causes
a Doppler phase shift in the reflected ultrasound, and DBP is recorded upon the cessation
of arterial retraction (63;64). This technique can also be used to detect the onset of blood
flow at SBP, a method that has been proven to be of clinical significance in certain
populations or individuals who prove difficult when using other BP measuring techniques
(eg. patients with very faint Korotkoff sounds) (64).
Peñáz/Wesseling-method (Finapres/Portapres)
The Peñáz/Wesseling-method is known as the Finapres/Portapres protocol.
Developed in the 1970’s, this method exploits the principle of the “dynamic, unloaded
arterial wall” (62;64;68). The sizes of the arteries of the pointer finger are gauged via an
infrared transmission plethysmograph mounted inside an inflatable cuff. The device is
programmed to detect increases in the arterial diameters of the fingers with increasing
BP; where appropriate increases in the air pressure within the cuff occur in order to
maintain constant arterial diameters, keeping the arteries in a partially-opened state
(62;64;68)

. The oscillations in the cuffs’ pressure are measured with an electronic pressure
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gauge, which provides an indirect measurement of the intra-arterial pressure waveform
and (together with the implementation of a pattern recognition program) the beat-by-beat
SBP, DBP and MAP (62;64;68). Although somewhat cumbersome, the Finapres also
enables readings to be taken over 24-hours while subjects are ambulatory, and thereby
also provides insight into daily BP variability (63).
Although this method gives an appropriate estimate of the acute changes in BP,
readings may be underestimated (or overestimated) in some populations when comparing
the observed values to those taken from the brachial artery (63). Due to the cost,
inconvenience, and relative inaccuracy for measuring absolute arterial BP, this method is
considered inappropriate for use in clinical settings (63).
Applanation Tonometry
Applanation tonometry is another method for the non-invasive determination of
arterial BP. This technique continuously monitors the fluctuations in arterial BP
throughout the cardiac cycle through the detection and collection of the arterial PP
waveform (69). The general principle of applanation tonometry is dependent upon the
structural characteristics and anatomical location of the selected artery, it must be
compressible (70) and must be located against a bone or rigid structure (63). For this
procedure, a small applanation tonometer probe (Millar Instruments Inc., Houston, Texas,
USA) is used as a pressure sensor and placed over either the radial (71) or the carotid (70;7275)

artery, where the tonometer must minutely compress or splint the artery against a bone

in order to obtain an accurate PP waveform (63). This technique depends upon the ImbertFick law, which states that the internal pressure of a completely elastic spherical body
equals the force exerted to flatten the body, divided by the flattened surface area (76). The
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assumptions of this law enable applanation tonometry to estimate arterial BP with
reasonable accuracy (76;77) and can provide pressure waves that are almost identical to
those obtained through intra-arterial measures (78).
Although this technique has consistently shown to provide accurate insight on
arterial BP, several limitations exist. Most importantly, the law by which this technique
is based assumes that the artery in question is infinitely thin, perfectly elastic and
perfectly flexible - none of which are true. Several other additional limitations also exist,
including i) investigator expertise (e.g., the positioning of the tonometer probe must be
precise and/or excessive hold-down force can skew arterial pressure readings), ii) motion
artifacts may influence the forces translated from the artery to the tonometer, and iii) the
calibration of the device requires the use of an external measurement device, such as an
automated oscillometer (77).

1.1.4 Pathophysiology of Hypertension
HT is considered the “silent-killer”, as it is currently labeled as the leading
modifiable risk factor for CVD-related morbidity and mortality worldwide (6). As
previously discussed in Section 1.1.1 Hypertension, HT afflicts over 7.2 million
Canadians (6), where the majority of those affected are women who are in their 6th decade
of life - a decade that coincides with the onset of menopause (10). Those with lower BP
are also at risk, where a positive relationship between resting BPs as low as 115/75
mmHg and CVD risk has been identified for individuals between the ages of 40 and 70
years, which doubles for each 20/10 mmHg increase (8). This risk is most applicable to
women within this age group who have sustained higher than normal BP (NT; ≥120/80
mmHg) (79). Therefore, identifying individuals who are at an elevated risk for developing
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HT (pre-HT postmenopausal women) are of utmost importance when trying to mitigate
the burden that HT places on the Canadian health care system. As such, several
hypertensive states have been identified and are defined below.
HT has no definitive symptoms; an individual is classified as HT following the
accurate determination of elevated BP on two or more separate occasions, if an individual
is on prescribed HT medications, or if they have been told, on 2 or more separate
occasions, that they are HT by their health care practitioner (6). The definition of HT has
recently been re-evaluated; stratifying individuals into one of four BP groupings based on
their resting BP measures, with healthy BP falling between ≤120/≤80 mmHg (9;80).
Individuals are classified as pre-hypertensive when displaying BP of 120-139/80-89
mmHg (9;80). Although those found to be pre-hypertensive are not considered to have an
established diseased state, this classification provides health care practitioners with an
opportunity to intervene in individuals who are at an elevated risk for the development of
HT (80). As the condition progresses, individuals are considered to have Stage I HT when
displaying BP between 140-159/90-99 mmHg, and considered Stage II HT (the most
severe) when displaying BPs ≥160/≥100 mmHg (9;80).
There is a widely held misconception that HT is a single disease and that it can be
managed with a single choice of treatment. However, HT is a heterogeneous disorder that
allows patients to be pathologically stratified according to their co-morbidities, and
allows for the identification of the most effective and specific treatment options for each
individual case (81). Various forms of HT have been identified and categorized based on
the relative cause or characteristics of the specific hypertensive case, where the most
commonly encountered forms have been identified as primary and secondary HT.
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Primary (Essential) Hypertension
HT can be of known or unknown causes. Primary HT (characterized by a
sustained SBP ≥ 140 mmHg and a DBP ≥ 90 mmHg) is the most prominent form of HT,
accounting for ~95% of the total cases (82). Although primary HT is commonly
considered to have no identifiable cause, it is suspected to manifest through the
interaction of an individuals’ inherited genetic traits and their exposure to certain
behavioral, environmental and lifestyle-related “hypertensinogenic factors” (81-83).
Hypertensinogenic factors are defined as a substance or situation that tends to increase BP
and include obesity, insulin resistance, high alcohol or salt intake, aging, a sedentary
lifestyle, excessive stress, low potassium intake, and/or low calcium intake (82;84;85).
Elevations in arterial stiffness (measured by the determination of arterial stiffness
indices) have also been found in primary HT (86;87). Carotid arterial compliance (CAC) is
one such index, representing the resistance provided by the walls of the carotid arteries
against the pulsatile output of the heart (88). Reductions in CAC occur as a result of
arterial wall structural reorganization in response to the prolonged exposure to elevations
in BP (86), and have been found to be correlated with target organ damage in HT-related
CVD (86). Reductions in CAC have been found to occur in concert with other CVD risk
factors, including advanced aging (75;89;90), smoking (89), and physical inactivity (75),
independent from the occurrence of HT. Therefore, reduced CAC can thusly i) contribute
to the establishment or ii) be a consequence of elevated arterial BP (75). Furthermore,
stiffer large arteries like the carotid artery are associated with the greater prevalence of
isolated systolic HT in postmenopausal women, and may partially explain the
acceleration in the rates of established postmenopausal CVD (88).
Although BP regulation is influenced by the previously described genetically
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determined processes, it is currently unknown which genes cause BP to vary (82).
Although an ideal genetic BP regulatory phenotype is known, countless phenotypic
variants occur within the general population; inherited BP could range from low normal
BP to severe HT (75). Certain hypertensinogenic factors, such as obesity, excessive
alcohol consumption, or insulin resistance also have important genetic components, and
their interaction with the inherited control of BP may also influence BP regulation (82).
Furthermore, the interaction between genetics and environment factors can also result in
the aberrant functioning of the regulatory processes that are in place to maintain arterial
BP homeostasis, including sympathetic nerve activity, the RAAS, endothelial-derived
factors, sodium excretion, vascular reactivity and cardiac contractility (82). The combined
contribution of these intermediary phenotypes determine an individuals’ TPR and Q, and
consequently BP (82), where the interruption of the normal regulation of any of these
processes can contribute to the establishment of HT.
A haemodynamic hallmark of primary HT is a persistent elevation of TPR that is
thought to occur through pathological SNS overdrive (91). Excessive SNS innervation can
affect the heart, increasing both HR and cardiac contractile force, both of which
contribute to pathological elevations in Q and sustained elevations of resting BP in HT
(91)

. Although excessive SNS activity has been identified in primary HT, the underlying

cause of this elevation remains equivocal.
Secondary (Systemic) Hypertension
Secondary HT occurs as a result of an identifiable cause, such as reduced renal
function or damage, pheochromocytoma, Cushing’s disease, certain cancers, or as an
adverse reaction to certain types of illicit drugs or medications (14). Although the number
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of potential causes of secondary HT seems daunting, this condition only accounts for a
small percentage of all HT cases, and commonly occurs as a co-morbidity to an identified
pathology (81;83).

1.1.4.1 Cardiac Output and Total Peripheral Resistance in Hypertension
HT is consistently characterized by the dysfunctional regulation of Q, TPR, or
both (81;83), suggesting that treatment and management options for HT should be aimed at
regaining homeostasis between Q and TPR.
Cardiac Output and Hypertension
Increased Q has been found in some younger, borderline HT individuals (81). If
the established HT is a result of increased Q, it can arise from one of two ways, i) from an
increase in fluid volume within the vasculature (preload), or ii) from increased cardiac
contractility via elevated cardiac neural stimulation (81). HT is associated with an
increased sympathetic outflow and reduced PNS activity, which represent aberrant
autonomic functioning and a reduced autonomic ability to modulate HR (92). The reduced
vagal innervation of the heart can result in chronic elevations of resting HR, which would
increase Q and contribute to sustained HT (93).
Total Peripheral Resistance and Hypertension
Dysfunctional modifications to sympathetic neural conductance contribute to the
impaired regulation of TPR and have been consistently observed in individuals with
clinically diagnosed HT. Several defining factors of the aberrant sympathetic responses
that are characteristic of HT include impaired buffering capacity of baroreflex (94;95) and
increased sympathetic nerve outflow/activation (95-97). With respect to the latter, SNS
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over-activity has been implicated in early and sustained HT (81). However, both of the
implicated neurovascular mechanisms seem to play an important role in the impaired
regulation of TPR in HT.
Multiple factors contribute to sustained elevations in TPR in HT, all of which
primarily affect pre-capillary vessels with lumen diameters ≤ 500 μm (98;99). The
increased stress placed on the arterial walls during sustained elevations in BP stimulates
structural adaptations in these resistance vessels that are characterized by reduced arterial
lumen diameter and an increased ratio of the vascular smooth muscle thickness (tunica
media) to lumen diameter, referred to as the media-to-lumen ratio (81). As previously
mentioned in Section 1.1.2 Arterial Blood Pressure, Poiseuille’s law states that vascular
resistance is positively related to both the length of the arterial system and the viscosity of
the fluid medium within the system (i.e. blood), and negatively related to the fourth
power of the arterial lumen diameter (15). As neither blood viscosity nor arterial length is
considerably altered with HT, any small changes in arterial lumen diameter can have a
profound impact on vascular resistance (14;36;81). The sustained elevation of TPR in HT
most closely reflects the minute changes of vascular structure that result in reductions in
arterial lumen diameter (100;101).
Outward hypertrophic remodeling is characterized by increased media-to-lumen
ratio that occurs as a result of the hypertrophy or hyperplasia of the vascular wall
components and is also characteristic of sustained HT (102). These structural adaptations
increase the arterial cross-sectional area (CSA) and contribute to a loss in the elastic
nature of the arteries (81;102). Vascular remodeling is an alternative process that mediates a
reduction in media-to-lumen ratio. This process is characterized by the rearrangement of
existing vascular material is such a way that results in a reduction of the external arterial
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diameter without modifications to the arterial CSA (81;98). Vascular remodeling has been
suggested as the primary vascular structural adaptation that occurs in response to
sustained elevations in BP (81).

1.1.4.2 Menopause and Hypertension
Menopause is a natural female phenomenon that involves the reduction in the
production and concentration of circulating estrogen. This process coincides with the 6th
decade of a woman’s life, where a relationship between the onset of menopause and
elevated CVD-risk has been identified and is well established (103). Estrogen acts
throughout the CVS in a protective manner through estrogen receptor activation and the
subsequently stimulated inhibition of smooth muscle cell proliferation and fibrosis,
attenuation of atherosclerotic plaque progression, and re-endothelialization of injured
vasculature. All of which ultimately contribute to cardiovascular health in both men and
women (103). As women enter menopause and experience large reductions in estrogen
production, the cardio-protective effects of estrogen are diminished, and as such, women
who display higher SNS activity are more likely to develop HT (104).
The prevalence of diagnosed HT in postmenopausal women exceeds that observed
in age-matched men (105), where sex-related differences in the neurovascular control of BP
are suggested as the primary mediator in the observed difference (104;106). In support of
this notion, women display lower autonomic support of BP regulation (107), with a
concomitant blunted vasoconstrictor response (108). For example, cardiovagal baroreflex
sensitivity and the systemic vascular response to an autonomic challenge (e.g., tilt) is
lower in HT women than in age-matched HT men (109;110). Ancillary to aberrant
autonomic regulation of BP in postmenopausal women, concurrent increases in arterial
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stiffness and modifications to Q may also play a role in the amplified rate of established
HT (88), and may also contribute to the increased occurrence of cardiovascular
complications in this population.

1.1.5 Recommendations for the Treatment of Hypertension
The traditional clinical objective when attempting to manage HT has been to
obtain resting BP within the 140-160/90-100 mmHg range, but recent evidence suggests
that lower BP (≥120/80 mmHg) should be the optimal treatment goal (79). As such,
recently updated HT-management guidelines suggest attaining lower BP values (<120/80
mmHg) in order to minimize the overall risk of CVD-related morbidity and mortality
(80;111)

.

1.1.5.1 Lifestyle Modifications For Hypertension
Lifestyle modifications (dietary modifications, increasing physical activity levels)
are the initial and most commonly suggested management options for HT (8;80;112;113).
Lifestyle modifications that solely depend upon the consumption of healthy nutritional
meals and participation in physical activity have been shown to reduce resting BP to
within normal range in many populations (8;80;112;113). Further lifestyle modifications can
also be employed in attempts to reduce an individuals’ exposure to other
hypertensinogenic factors, including reducing dietary sodium intake, limiting alcohol
consumption, maintaining a healthy body weight. Following the Dietary Approaches to
Stop Hypertension (DASH) can also potentiate the hypotensive benefits achieved through
the participation in regular physical activity (8;80;112;113).
The DASH diet pertains to nutritional modifications that focus on the inclusion of
a large amount of vegetables, fruits, and low-fat dairy products in the diets of persons
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with or without HT (114). Some individuals respond to the nutritional modifications of the
DASH diet to a greater extent than others, but the potential of the DASH diet as a HT
treatment option remains apparent, as those who do respond to the diet experience
reductions in resting BP that mirror those that can be obtained through a single,
pharmacological HT treatment (80). The DASH diet has been found to be significantly
associated with reductions in SBP regardless of sodium-intake, although the reductions
became more pronounced in individuals on high-sodium diets compared to those on lowsodium diets (84;114). A DASH diet with a concomitant reduction in sodium intake to what
is currently considered low levels (67 ± 46 mmol/day) can produce reductions in mean
SBP of up to 7 mmHg in NTs and 11 mmHg in HTs (114). The observed reductions in
resting BP following simple lifestyle modifications like following the DASH diet and
reducing excessive sodium intake plays an integral role in the prevention and/or
management of HT.

1.1.5.2 Pharmacotherapy for Hypertension
While lifestyle modifications have been shown as an effective management and
prevention measure for HT, many individuals often require additional pharmacotherapy
in order to reduce BP to target levels (8;80;111). As previously mentioned BP is regulated
through a myriad of neural, humoral and locally produced mechanisms, which suggests
the potential for the intervention in the aberrant functioning of these mechanisms through
pharmacological HT therapy. In morbidly progressed or resistant HT cases, more than
one medication may be needed to adequately control BP (80). Commonly prescribed antiHT medications include diuretics, angiotensin converting enzyme inhibitors (ACEIs),
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angiotensin receptor blockers (ARBs), beta-blockers (BBs) and calcium channel blockers
(CCBs) (80).
Diuretics
Diuretics (thiazide or loop) are the recommended first-line pharmacological
intervention for HT (80) and both act to inhibit solute re-absorption (i.e. Na+) from the
renal tubules increases sodium excretion (natriuresis) and, through elevated osmotic
drive, increases H2O excretion and urinary output (diuresis) (14). Although the increased
urinary output and fluid removal occurs secondary to the inhibition of renal tubular
sodium re-absorption, the overall effect results in reductions in total blood volume and
arterial BP (14;45).
Angiotensin-Converting Enzyme Inhibitors
As previously described, the conversion of angiotensin I to angiotensin II is
dependent upon the action of the angiotensin converting enzyme. The ACEI-meditated
inhibition of this process reduces the production of the vasoconstrictor angiotensin II and
thereby reduces the vascular tone and, therefore, effectively lowers BP (14;83). The ACEImediated reduction in circulating angiotensin II and the concomitant reduced arterial BP
is translated to reductions in renal pressure and glomerular filtration rate which increases
sodium and H2O excretion rate and reduced total blood volume (14). These ACEI actions
provide the basis for the chronic BP reductions that are required to treat and manage HT
(14)

.

Angiotensin II Receptor Blockers
ARBs are competitive antagonists for the angiotensin II receptors, acting to reduce
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angiotensin II receptor activation and the subsequent vasoconstrictive effects that are
initiated as a result of this binding (14;83) which contributes to reductions in TPR and
facilitates reductions in BP (14). ARBs also inhibit renal ionic re-absorption and
aldosterone secretion, thus increasing fluid excretion, reducing total fluid volume and
blood volume and thereby contributing to reductions in BP (14;83).
Beta-Blockers
BBs are competitive antagonists at the sympathetic ß-adrenergic receptors of the
heart and vasculature (14) which act to reduce the work of the heart by preventing the
sympathetic enhancement of heart rate, cardiac metabolism and vascular tone (14;83). The
combined effect of BBs on cardiac functioning results in the reduction in both Q and
TPR, which mediates reductions in BP (14;83).
Calcium Ion Channel Blockers
The CCB utilized for BP management are classified as dihydropyridine CCBs,
which effectively block membrane-bound voltage-gated Ca2+ channels in cardiac and
vascular smooth muscle to impede the voltage-dependent transit of Ca2+ ions across
cellular membranes and thereby inhibit the Ca2+-dependent initiation of VSMC
contraction (115). The reduction of the contractile tone of the VSMC results in reductions
in TPR, and thus decreased BP (14;83).
Effectiveness of Pharmacotherapy in Hypertension Management
In 2008, Canadians spent an estimated $28 billion dollars on pharmaceuticals,
with approximately 20% of the spending focused on hypertensive medications (116;117).
However, the use of pharmacological interventions for HT treatment has been found to be
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effective in less than 50% of treated patients (118). Furthermore, pharmacologicallymediated reductions in BP to levels that are within the normal range remains elusive to a
vast majority (~85%), and the use of pharmacology as an adjunct-treatment has less
success in managing elevated BP in older woman than their age-matched male
counterparts (119). Results from the Framingham Heart Study suggest that ~72% of treated
individuals over the age of 60 are not able to attain target BP values through
pharmacological interventions alone (120). In addition, evidence suggests that medicated
individuals who have attained adequate BP control may still exhibit elevations in
sympathetic outflow (121). This persistent elevation in SNS activity may explain the high
rates of morbidity and mortality among individuals medicated for HT (121), despite
clinically significant, pharmacologically-mediated reductions in arterial BP.

1.2 Exercise and Hypertension
Physical activity can reduce resting BP, and as such, chronic exercise has become
an integral component of HT management and prevention programs (9;13). The American
College of Sports Medicine has developed HT-based exercise recommendations,
suggesting that HT individuals participate in moderate intensity aerobic exercise (40 ≤
60% of an individual’s heart rate reserve) for 30 to 60 minutes a day, between 3 to 7
times per week in order to garner the associated health benefits (9). Resistance training
(RT) is recommended as an adjunct treatment, to be performed, 2 to 3 times per week at
an intensity that would allow for 12 to 15 repetitions per exercise, for every major muscle
group (8). Currently there are no endorsed exercise guidelines for isometric exercise
training.
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1.2.1 The Effects of Exercise Training on Arterial Blood Pressure
Endurance (Aerobic) Exercise Training
A collection of meta-analyses collectively confirm the ability of chronic aerobic
training (AT) to reduce resting BP in HT and in those with normal arterial BP, regardless
of the exercise modality (i.e. walking, running, cycling), intensity (30 to 90% VO2max),
frequency (1 to 7 days per week), or duration (30 to 60 minutes per day) (8). The age of
the participants enrolled in these studies ranged from 18 to 79 years (median ~ 45 years),
implicating the ability to experience aerobically-induced reductions in resting BP
throughout the lifespan (8). Furthermore,

HT individuals consistently experience more

dramatic reductions in resting BP following AT (HT: ~7/6 mmHg; NT: ~2/2 mmHg) (65).
To determine the effects of training-induced modifications to Q versus TPR and
their relative contributions to the training induced reductions in resting BP, work by Spina
et al. (122) focused on the cardiac functional adaptations to AT in a healthy, elderly
population (N=31; 16 females, 64 ± 3 years). Sex-based differences in the cardiovascular
adaptations to training were observed, where training-induced improvements in resting Q
(as determined by elevations in SV) occurred in the male participants only, while
improvements within the female participants were the result of enhanced arterial-venous
O2 extraction (122). As such, reductions in resting Q are not typically expected in women
with above normal BP following exercise training. These observations implicate reduced
TPR as the primary mechanism that is responsible for reductions in resting BP in this
population (8).
Reductions in TPR are likely mediated through vascular changes (i.e. increased
endothelial-dependent vasodilation), arterial structural changes (i.e. increased CSA of the
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resistance arterioles), and/or functional changes (i.e. NE receptor desensitization and
increased NO availability and release). Neurological modifications (reduced sympathetic
nerve activity) and genetics may also be implicated in the physiological adaptations to AT
(8)

.

Dynamic Strength (Resistance) Training
Resistance exercises involve controlled concentric and eccentric movements,
where muscles are shortened (concentric) or elongated (eccentric) while under tension
and produce contractions that change the angle of the joints throughout the activity (123).
Historically, the effects of RT on resting BP has been equivocal, however, two recent
meta-analyses (N=≥ 320 male and female NT and HT subjects; 182 exercise, 138 control)
found statistically significant reductions of ~3 mmHg for both SBP and DBP following
chronic RT (124;125). Although this reduction may seem modest from a clinical standpoint,
reductions of 3 mmHg among the average population has been estimated to mediate a
significant reduction in the occurrence of severe CVD-related events and all-cause
mortality (126;127).
The mechanism(s) responsible for the reduction in arterial BP that is provided by
RT are similar to those seen with AT, where vascular, structural, functional and/or
neurohumoral adaptations have been implicated in the exercise-induced reductions of
TPR (8).
Isometric Handgrip Training
Isometric exercises incorporate the generation of muscular force without changing
the length of the exercising muscle (128). Over the last decade, isometric handgrip training
(IHG; a novel form of exercise training where participants perform multiple, timed,
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sustained contractions on a programmed handgrip dynamometer, performed at a set
percentage of their maximal effort (MVC) for up to 10 weeks) has received attention in
the literature for its positive effects on resting BP among healthy and clinical populations.
For example, Wiley et al. (129) employed a randomized controlled, IHG-training protocol,
(4, 2 minute isometric contractions at 30% of their MVC, where each contraction is
separated by 3 minutes of rest, 3 times per week for 8 weeks) and observed average
reductions in resting SBP and DBP that reached ~13 and 15 mmHg, respectively. A
second protocol, with a slightly modified IHG-training protocol (4, 45 second
contractions at 50% MVC, separated by 1 minute of rest, 5 times per week for 5 weeks)
was employed and produced statistically significant reductions in resting SBP and DBP of
~10 and 9 mmHg, respectively.
Ray and Carrasco (130) examined the effects of 4, 2 minutes IHG contractions held
at 30% MVC, performed 4 times per week for 5 weeks in NT adults (N=17; 19 – 35
years, 46% women), reporting reductions of ~5 mmHg for resting DBP, while observing
no statistically significant reductions in resting SBP (~3 mmHg). More recently, the
effects of IHG training on arterial BP in NT individuals (N=13; 27.5 ± 14.2 years, 23%
women) was further investigated by McGowan and colleagues (131), where an 8 week
unilateral IHG protocol (consisting of 4, 2 minute IHG contractions at 30% MVC using
the non-dominant hand, separated by a 4 minute rest period between contractions) was
employed. Similar reductions in resting BP (~5mmHg SBP) were observed using this
modified isometric exercise protocol.
In 2008, Millar and colleagues (132) provided further evidence of the BP lowering
effects of IHG training in an older, NT population (N=49; 66.4 ± 0.9 years; 57% women).
Through the use of an 8 week bilateral IHG training protocol (as previously described),
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reductions in both SBP and DBP of 10 mmHg and 3 mmHg, respectively, were observed.
Of particular interest, females responded with greater reductions in BP than did their male
counterparts (female slope coefficient = -0.55 vs. male slope coefficient = -0.20, p<0.01)
and the training effects appeared to be most pronounced among the older participants (132).
In 2003, the clinical effectiveness of IHG training was explored in HT individuals
(N=17; 41% women) using a 10 week bilateral IHG training protocol (as previously
described). The IHG training produced significant reductions in both SBP and DBP (19
mmHg and 7 mmHg, respectively) in this HT population (92).
In 2007, McGowan and colleagues (133) examined and compared the effects of an 8
week bilateral and unilateral (as previously described) IHG training program in
individuals medicated for HT (N=16; 25% women). SBP was reduced by ~15 mmHg and
~9 mmHg for the bilateral and unilateral protocols, respectively (133). These results
provide additional evidence of the effectiveness of IHG training as a management option
for HT (92).

In the same year, a multilevel analysis investigated the effects of IHG

training in medicated HT (118), finding combined reductions of ~6 mmHg and ~3.0 mmHg
for SBP and DBP, respectively (118), which solidified the use of this exercise modality as
an effective exercise management option for those with HT.
This collective work was recently extended by Stiller-Moldovan et al. (2012) who
observed clinically-relevant (8) reductions in 24-hour ambulatory BP in well-controlled,
medicated hypertensives following IHG training (N=11 IHG training group, N=9 control
group; 50% females).
Although there is much data to support the effectiveness of IHG training in
reducing resting BP, the mechanisms responsible for this reduction remain equivocal.
Potential mechanisms responsible for reduced vascular resistance following exercise
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training have been suggested and are thought to be the result of neurohumoral and/or
structural adaptations within the CVS. Improvements in the neurohumoral regulation of
TPR that would mediate reductions in resting BP include reduced SNS innervation to the
vasculature and/or improved local vasodilator influence on the VSMC (i.e. NO), while
increased arterial lumen diameter (which would increase arterial radius and thus reduce
resistance to blood flow and hence arterial BP) and/or reduced arterial stiffness (by means
of improved arterial compliance) have been hypothesized as the potential structural
vascular adaptations to training that would permit reductions in TPR and subsequently,
BP (133).

1.3 Arterial Stiffness
Increased central arterial stiffness is a cornerstone of the aging process and occurs
as a result of many chronic diseases, such as diabetes, atherosclerosis and renal failure
(134)

. Arterial stiffening is also correlated with increased CVD risk, myocardial infarction,

heart failure and cardiovascular-related mortality (135). Clinical surrogate markers of
vascular stiffness, including elevations in PP and isolated systolic HT also increase with
age and these associated conditions (80). Arterial stiffness alters both resting and stressinduced haemodynamics and energy expenditure within the CVS. The effect of this
stiffening predisposes an individual to the previously mentioned CVDs, lowers the
symptom threshold, contributes to orthostatic hypotension and increases perception of
dyspnea upon exertion in older adults (134).

1.3.1 Structural Components of Arterial Stiffening
The stability, resilience, and elasticity of the arterial system depend upon the two
major extracellular matrix (ECM) scaffolding proteins: collagen and elastin, while others
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such as fibronectin and proteoglycans provide additional structural support (134). Collagen
provides structural integrity, while elastin promotes elasticity and distensibility.
The production and degradation of collagen and elastin within the ECM is
regulated by activated serine proteases and matrix metalloproteases (MMPs) (136), which
are grouped as collagenases, elastases or gelatinases (137). The MMP regulated
degradation of collagen and elastin within the ECM results in the production of broken
and frayed collagen and elastin molecules, which reduces vascular elasticity and increases
arterial stiffness

(138;139)

. Arterial stiffening is further enhanced through the degratory

and inflammatory processes that occur within the ECM following gelatinase activation
(116)

via an inflammatory-mediated dysregulation of MMP homeostasis that results in the

overproduction of abnormal collagen, reduction in normal elastin and contributes to
increases in arterial stiffening (140). Furthermore, the deposition of additional structural
components within the ECM, including chondroitin sulfate, heparin sulphate,
proteoglycans, and fibronectin can also contribute to elevations in arterial ECM thickness
and stiffness with age (141).

1.3.2 Pathophysiology of Arterial Stiffening
Arterial stiffening develops as a result of the complex interaction between stable
and dynamic modifications of the vascular wall that involves both structural and cellular
components of the arterial system (134) (Figure 10; page 120). The arterial ECM
structural organization is influenced by haemodynamic forces within the CVS and
circulating compounds, such as circulating hormones, sodium chloride, glucose, and
insulin (49). Furthermore, it is important to note that arterial stiffening is not uniformly
distributed through the arterial tree, but rather has been found to occur in isolated patches
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(137;142)

, where the stiffened arterial segments are most often observed in the central

conduit arteries, like the carotid artery (86). The aging process or conditions like HT can
augment the vascular changes that occur with arterial stiffening and accelerate the
pathogenic progression of the diseased state (143;144). While increases in intimal-media
thickening (IMT) and stiffening of the vasculature are hallmark characteristics of arterial
aging, increased central arterial lumen diameters have also been observed (144). These
increases are thought to occur as a compensatory mechanism, where the arterial system is
structurally modified in response to increases in IMT in an attempt to maintain adequate
haemodynamics within the CVS (90;135). However, the effect of arterial stiffening with
aging on BP is not often overcome exclusively through this process (86;145).
Lipids and Arterial Stiffening
The relative degree that lipids contribute to arterial stiffening remains unclear.
Lipids have been implicated as both a beneficial (136) and negative (139) influence of
arterial ECM and wall composition, both of which depend upon the examined location
within the arterial tree. Although the pathophysiology of atherosclerosis and arterial
stiffening occur as a result of similar inflammatory, protease and oxidase-mediated stressremodeling processes, causality remains unclear as both pathologies are commonly
concurrently encountered (134).
Cellular Role In Arterial Stiffening
Arterial stiffness can also be affected by endothelial functioning and VSMC tone.
The tonic state of the VSMC can be modified via a myriad of factors, ranging from the
mechanostimualtory influence that occurs as a result of modified Ca2+ ion flux within the
cells due to cellular stretch that accompanies VSMC contraction, and/or in response to
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circulating or locally produced vasoactive substances, such as angiotensin II, endothelin1, transforming growth factor beta (TGF-ß), reactive oxygen species (ROS), and NO (134).
Endothelial dysfunction relates to the inability of the endothelium to respond to
circulating vasoactive substances and/or initiate the production of endothelium-derived
vasodilatory (i.e. NO) or vasoconstrictive (i.e. endothelin-1) substances (146). Endothelial
dysfunction emanates, in part, from an imbalance between the circulating vasodilatory
and vasoconstrictive substances within the vasculature (147), where NO expression may be
reduced (148), and /or its production and release may be diminished as a result of the
elevated expression of an endogenous NO synthase inhibitor (asymmetrical
dimethylarginine; ADMA), activation of ROS via stress, hormones and their subsequent
effects on the endothelium (149). Most notably, plasma ADMA concentrations are
positively correlated with carotid arterial IMT (F = 11.1, p = 0.03), implicating aberrant
ADMA regulation with the occurrence of increased arterial stiffness and other CVD risk
factors (150).
Furthermore, recent work by Peng et al. (151) highlights a positive feedback
mechanism in place within the vasculature that acts to potentiate arterial stiffening and
endothelial dysfunction, where the normal shear stress-stimulated endothelial NO
production is significantly reduced when endothelial cells are exposed to realistic
pulsatile perfusion after being mounted to a less distensible, more stiff silastic tubing
model. The observations suggest that the ability of the arterial wall to stretch impacts
endothelial mechanotransduction and functioning to a greater degree than a flowmediated, pulsatile stimulus (151), and the lack thereof contributes to the exacerbation of
arterial stiffening.
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Transforming Growth Factor Beta
TGF-ß has been identified as one of the primary cytokine released at the site of
local tissue damage or chronic inflammatory situations that are responsible for the
regulation of the initiation and termination of tissue repair processes (152). TGF-ß exists in
three isoforms (TGF-ß1, TGF-ß2, and TGF-ß3) and binds to its specific VSMC and
fibroblast cell surface receptors (TGF-ß type I (TßRI) and type II (TßRII) receptors) (152).
Aberrant regulation of TGF-ß underlies the development of local inflammation (eg.,
TGF-ß acts as a chemokine for leukocyte and fibroblast recruitment) (152) and the
subsequent tissue fibrosis (via inhibition of MMPs and elevated expression of ECM
proteoglycans, fibronectin and collagen) that is characteristic of countless disorders (152)
and is associated with arterial stiffening in aging (153).
Neuroendocrine Role in Arterial Stiffening
The RAAS plays crucial role in the regulation of total fluid volume and arterial
BP, however, it is also an important regulatory mechanism that can influence the adaptive
responses of the CVS to BP abnormalities as well. Activation of the RAAS results in
modifications of the ECM composition within the CVS by stimulating the expansion of
the matrix and increasing fibrosis (154). The RAAS-driven fibrosis is characterized by
increased inflammatory cells recruitment and the activation of the redox-sensitive NF-κB
pathway within the vasculature (155). This pathway results in the modulation of local gene
expression to favor the promotion of elevated hyperplasia while reducing cellular
senescence, all of which have been found to contribute to arterial stiffening (155). The
RAAS also contributes to arterial stiffening via angiotensin II, as angiotensin II-mediated
production of ROS and the subsequent endothelial NO synthase enzyme uncoupling also
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contributes to the endothelial dysfunction that occurs with arterial stiffening and HT (156).
This process can also activate the NF-κB pathway, potentiating the aberrant structural
organization that occurs with arterial stiffening (157). Angiotensin II can also directly
affect arterial structural organization by promoting reduced elastin synthesis, initiating
collagen formation and stimulating ECM remodeling and vascular hypertrophy (158;159).
Aldosterone of the RAAS promotes vascular stiffness through the stimulation of VSMC
hypertrophy and fibrosis by stimulating increased production and deposition of
fibronectin within ECM (160). Circulating concentrations of aldosterone are also closely
linked to that of endothelin-1, where infusions of aldosterone increase ET1 production in
murine models (161). This relationship is important to consider, as ET1 produces
vasoconstrictive and fibrotic effects within the vasculature through processes that are
independent of aldosterone (161) and suggests that there is a compounding effect of
aldosterone and ET1 on the CVS that occurs in concert and contributes to the progression
of arterial stiffening. Lastly, excessive tissue RAAS activity occurring in response to
defects in the sodium-modulated tissue responses of the renal and adrenal systems also
contributes to increased vascular tone, arterial stiffness, and other pathologic angiotensin
II-like dysfunctions in local tissues in HT (162).
Genetic Role in Arterial Stiffening
A number of genetic polymorphisms are associated with elevated arterial
stiffening, including those within the ACE or angiotensin type I receptors (175), ET1 A and
B receptors (180), collagen type-Iα1 (181), fibrillin-1 and IGF-1 (182) loci. However, these
polymorphisms have only been noted in small scale studies using participants from
specific ethnic populations and have yet to be identified in the general population.
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1.3.3 Methods of Measuring Arterial Stiffness
Several predictive and direct, non-invasive methods have been developed for the
evaluation of arterial stiffness at a variety of sites throughout the arterial tree. These
methods involve the determination of arterial stiffness indices that are used to describe
the structural organization, mechanical properties and functioning of the vasculature. The
stiffness indices include the ß-stiffness index, pressure-strain elastic modulus (Ep),
distensibility co-efficient (DC), augmentation index (AIx), and arterial compliance.
ß-Stiffness
ß-stiffness is one of the most commonly employed clinical markers of
atherosclerosis and arterial stiffening (163). ß-stiffness is a unit-less index used for the
assessment of arterial viscoelasticity as the mathematical formula used for it derivation
adjusts the index for the distending pressure within the arteries (164). ß-stiffness is
determined following the measurement of arterial diameters and PP through the cardiac
cycle according to the following formula: ß = ln(Ps/Pd)/[(Ds – Dd)/Dd], where ln is the
natural logarithm, Ps is the systolic arterial BP, Pd is the diastolic arterial BP, Ds is the
maximal arterial diameter at peak systole, and Dd is the minimum arterial diameter at
peak end diastole (165). Higher values of ß indicate arterial stiffening (165). As a measure of
arterial stiffness, ß is less pressure-dependent than others (i.e. Ep) and is therefore more
reliable and reproducible (165).
Pressure-Strain Elastic Modulus
The Ep is a measure of arterial stiffness that is based on the relationship between
stress and strain within the circulatory system (166). Stress is a measure of how strong a

45

M.H.K. Thesis – M. Gregory

Windsor – Applied Human Performance

material is [i.e. how much external force are the internal forces of a material able to
withstand without succumbing to physical deformation or destruction (166)], and can be
mathematically determined by the formula: σ = F/A, where

is stress (N/m2 or Pa), F is

the force applied (N), and A is the CSA of the material (mm2 or cm2) (166). Strain
describes the relative stretch of a material or object in response to elevations in external
or internal forces (166), and can be mathematically determined by the formula: ε = Δl/lo,
where is strain (unitless), ∆ is the extension of the length of an object following the
exposure to an external force, and

is the original length of the object before the

external stress was applied (166).
Ep is used to describe the extent to which a material will stretch (i.e. how much
strain will be experienced) as a result of being exposed to a given amount of external
force (i.e. stress) (165). Ep is determined by the following formula: EP = (Ps – Pd)/[Ds –
Dd)/Dd], where Ps is the systolic arterial BP, Pd is the diastolic arterial BP, Ds is the
maximal arterial diameter at peak systole, and Dd is the minimum arterial diameter at
peak end diastole (165). Higher values for Ep indicate reduced arterial elasticity (165). As
the derivation of Ep relies on the differences between SBP and DBP, the accuracy of this
technique is highly dependent upon an accurate assessment of arterial BP (165).
Distensibility Co-efficient
Distensibility describes the ability of a material to expand or stretch in response to
an applied force (167). Within the CVS, distensibility is used to describe the ability of an
artery to stretch in response to the pulsatile output of the heart. DC represents the stress
on the arterial wall through the relationship between the relative changes in the CSA of an
artery per unit pressure (187) and is determined using the following formula: DC =
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[π(Ds/2)2 – π(Dd/2)2 /π(Dd/2)2]/ΔP, where Ds is the maximal arterial diameter at peak
systole, Dd is the minimum arterial diameter at peak end diastole, and ΔP is the local
pulse pressure (74). Lower values for DC reflect reduced arterial distensibility and
elevated arterial stiffness (168).
Augmentation Index
The AIx describes the degree that BP is augmented by the arterial system (165).
The AIx is determined via applanation tonometry and the subsequent analysis of the PP
waveform for the calculation of the difference between the maximal arterial pressure and
that at the inflection point of the same wave (165). This difference is used to determine AIx
using the following formula: AIx = (ΔP/PP) x 100, where ΔP is the difference between
peak SBP and the inflection point of the arterial pressure waveform, and PP is the arterial
pulse pressure (165). AIx is expressed as a percentage of arterial PP and describes the
degree that the central aortic pressure is augmented by the reflected pulse wave (165). AIx
values are negative in individuals where the velocity of the reflected pulse-wave is low
(i.e. children) and positive when the velocity of the reflected wave is high (i.e. the
elderly) (165), where elevations in AIx are associated with an elevated cardiovascular risk
(169)

.

1.4 Arterial Compliance
Arterial compliance is defined as the change in the CSA (ΔA) of an artery per unit
of pressure (ΔP) (71;164;165), and is a quantitative and qualitative assessment of the
viscoelastic properties of the arterial wall (71). Arterial compliance reflects the ability of
the large central and peripheral conduit arteries to buffer the pulsatile output of the heart
(164)

. During systole, the elasticity of the central arteries (i.e. aorta, carotid) reduces left
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ventricular wall stress by buffering the rise in peak systolic pressure (170). During diastole,
the stored energy is thusly released and facilitates organ perfusion throughout the cardiac
cycle (170). The relative diameter change of the artery from its maximum at peak systole
to its minimum at diastole reflects the compliance of the artery (171). Under normal
circumstances arterial elongation during systole is negligible (168), allowing for the
assumption that an increase in the volume of an arterial segment is exclusively the result
of increased arterial diameter (171). Thus, arterial compliance can be determined based on
the variation in the CSA and BP within an artery throughout the cardiac cycle (168;171).
This definition suggests that any modifications to either the arterial CSA or the pressure
exhibited therein will affect arterial compliance (or stiffness). Elevations in PP provide a
stimulus that will increase arterial stiffness (86;172) and have been found to be an
independent risk factor for CVD (173;174). The conservation of large artery compliance is
essential for the dissipation of arterial PP, and provides the capillary beds with the
appropriate pressure to allow for normal fluid exchange with the extra-vascular
environment while preserving the structural integrity of the fragile capillary walls (102).
The curvature of the PP waveform is influenced by the interaction of left ventricular
mechanics with the systemic arterial system, which allows for the reflection of this
waveform to be used to describe many features of the pressure and flow mechanics within
the CVS (175). The intensity of the pulse wave reflection contributes to the establishment
of a number of cardiovascular pathologies, including reductions in arterial compliance
(102;171;176)

. In HT, the structural adaptations that occur within the vasculature result in

reductions in vascular lumen diameter and intima-medial thickening, all of which
contribute to the loss arterial elasticity and increases in PP and thereby reduce arterial
compliance and exacerbate the arterial stiffening process (102;171;176).
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1.4.1 Assessment of Arterial Compliance
Arterial compliance can be evaluated three ways: i) systemically (observing the
ratio of PP to SV), ii) regional or segmentally (indirectly using pulse-wave velocity
(PWV = distance (m) / transit time (sec) over the arterial segment)), or iii) locally
(ΔA/ΔP) (71).
Systemic Arterial Compliance
The method used to determine systemic arterial compliance estimates arterial
elasticity throughout the systemic circulation through the use of the ‘area method’ (177),
which is performed by placing a hand-held Doppler flow velocimeter over the
suprasternal notch at the base of the neck to estimate ascending aortic blood flow while
concurrently performing applanation tonometry to estimate the aortic PP (177). Systemic
arterial compliance is then calculated according to the formula: SAC = Ad/R(ΔP), where
R is an estimate of TPR (derived as MAP/mean ascending aortic blood flow), Ad is the
area under the diastolic pulse pressure waveform, and ΔP is the aortic PP (177). This
method determines systemic compliance based on estimates provided from models of the
circulation (87), and thus, has been considered a rather crude approximation that does not
provide the means for the accurate evaluation of arterial elasticity (71;87).
Regional or Segmental Arterial Compliance
Regional or segmental arterial stiffness is indirectly determined by measuring
PWV over a certain arterial segment (71). PWV in different regions can be measured
using a variety of instruments, including the Complior (Colson, Paris, France), the Wall
Track System (Pie Medical, Maastricht, Netherlands), the SphygmoCor (PWV Medical
Pty Ltd., Sydney, Australia) and other customized devices. PWV is calculated using the
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formula: PWV = distance/transit time, where distance (m) is the physical measured
distance between the two pressure transducers on the selected arterial segment, and
transit time (s) represents the time delay between the feet of the proximal and distal PP
waves (71).
The Complior is a semi-automated device that uses pressure transducers to
determine the beat-to-beat time-delay between PP waves at two ends of an arterial
segment (71). When the distance between the transducers is entered into the device, PWV
is automatically determined and reported as the mean ≥ 10 consecutive pressure
waveforms (178). As the Complior allows for the simultaneous acquisition of the arterial
PP waves from two arterial sites, it is assumed to the most accurate technique to
determine regional arterial PWV (71). The SphygmoCor and Wall Track System measure
the time-delay between the R-wave of the electrocardiogram (ECG) and the feet of the
pressure and distension waveforms within specific arterial segments (71). Similar to the
Complior, PWV is calculated using the SphygmoCor and Wall Track System by
determining the transit time between the PP waves at two ends of an arterial segment and
the distance between the transducers (71). However, the latter techniques hold several
benefits over others, as they do not require hand-held applanation tonometry for PP
determination (instead, the pressure transducers are fixed over the desired locations using
Velcro straps) and require very little training time (a few days to weeks) for new
investigators to obtain reproducible measurements (71).
PWV is also inversely related to the arterial DC (71), and as such, can be indirectly
determined via the Bramwell-Hill formula: PWV = √1/(ρ x DC), where

represents the

density of the blood and DC represents the distensibility coefficient (71;179).
A major limitation to these techniques lies within the ability to accurately measure
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the appropriate distance for its inclusion in the PWV calculation. Distance can be
estimated with accuracy through the direct measurement between the two pressure
transducers in situations where a relatively straight arterial segment is being measured
(i.e. the brachial-radial arterial segment (71). However, the distance
measurement/estimation becomes a major limitation when the measured arterial segments
are not straight or if the proximal and distal pulse waves are recorded from different
arterial axis sites, as the pulse waves propagate in opposite directions at these locations
(i.e. the carotid-femoral segment) (71). The identification of the foot of the pressure wave
may also prove problematic during data analysis, where accuracy primarily depends on
the sampling rate employed and the technical skills of the investigator performing the
measurements (71).
Local Arterial Compliance
The local arterial compliance is defined as the compliance of a given artery per
unit of length, representing the change in the CSA of the artery per unit of pressure (71).
Arterial dimensions are commonly measured using ultrasonography and/or echo-tracking
techniques (NIUS02 and WTS), while PP is determined using applanation tonometry
(74;75;88;164;180;181)

.

CAC is a local, non-invasive assessment of carotid arterial compliance, which
describes the ability of the carotid arteries to buffer the pulsatile output of the heart (204).
Carotid arterial diameters are commonly obtained from the left carotid artery via B-mode
ultrasonography while PP waveforms are obtained from the right common carotid (74).
The arterial diameters are then measured leading-edge to leading-edge (74;182-184) with a
high resolution linear transducer that is placed longitudinal to the artery, 1-2 cm proximal
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to the carotid blub (74;75;164;180;181;183). After which, continuous digital recordings of
arterial diameter and PP fluctuations are obtained for at least two cardiac cycles for
offline analysis (74). Local arterial compliance is then calculated using the following
equation: CAC = [π(Dmax/2)2 – π(Dmin/2)2]/ΔP, where ΔD is the change in arterial
diameter from systole (Dmax) to diastole (Dmin), and ΔP is the arterial PP (74;164;180;181).
CAC measured within older female populations has been observed to range from 0.040.14 mm2/mmHg (181;185;186).
Several limitations to this technique exist, primarily concerning the accurate
determination of PP. Although applanation tonometry is considered more accurate and
appropriate than the Finapres for PP determination, this technique has also been found to
overestimate PP in certain situations, where some investigators have reported unreliable
magnitudes in the tonometrically-obtained PP (187). Furthermore, the calibration of the
tonometer to a PP determined from a reference artery (i.e. the brachial artery) is important
to maintain the accuracy of the instrument (71). This practice is based on the observation
that the MAP is constant and that DBP does not substantially change throughout the
arterial tree (170). Following calibration, applanation tonometry is performed at the target
and reference arterial sites to verify the calibrated accuracy (71), and to ensure a reliable
PP is obtained for the calculation of CAC.

1.4.2 Reduced Arterial Compliance and Hypertension
The elastic nature of the arteries is diminished as stiffening progresses to the point
where the central arteries are no longer able to effectively buffer the pulsatile output of
the heart, resulting in the progressive elevation of SBP and reduction in DBP (188). The
pathologic elevation of SBP facilitates a rise in left ventricular workload (189) (initiating
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left ventricular hypertrophy), while the reduction in DBP impairs coronary perfusion (190).
A cyclic relationship is soon developed as both of these processes place unfavorable
stress on the CVS and contribute to sustained stiffness-related elevations in arterial BP
(188)

.
Reduced CAC is characteristic of HT, where sustained elevations of MAP and PP

stimulate increases in arterial wall thickness (182) in an attempt to mediate the
normalization of arterial wall stress (191), and could potentiate the development of
atherosclerosis in these popualtions (192). Stiffer large arteries like the carotid artery are
associated with the greater prevalence of isolated systolic HT in postmenopausal women
and may partially explain the accelerated rates of established CVD within this population
(88)

. Although elevations in BP contribute to arterial stiffening, the intrinsic effect of

aging on the vasculature also poses an independent threat to cardiovascular health, where
reductions in compliance from normal values can span between 25% and 45%, depending
upon the individuals` level of habitual exercise participation (75), or the use of hormonereplacement therapy (HRT)

(164)

.

1.4.3 Treatment Recommendations for Reduced Arterial Compliance
Several management options for arterial stiffening have been identified, and as in
HT-management, the treatments available are primarily associated with the use of
pharmacotherapy BP in combination with various lifestyle modifications (i.e. reductions
in dietary salt intake (193) and increasing physical activity levels).
Pharmacotherapy for Reduced Arterial Compliance
Pharmacological treatments to reduce arterial stiffening include those that are
directly aimed at modifying the structure (e.g., nitrates) or those involved with modifying
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the physiological stresses within the arterial system via reductions in BP (e.g., angiotensin
II and aldosterone antagonists(194;195)).

1.5 Effects of Exercise Training on Arterial Compliance
Endurance (Aerobic) Exercise Training
Aerobic exercise has long been considered an effective intervention method for
arterial stiffening (134). During AT, the continuous elevated pulsatile output from the heart
occurs at the appropriate intensity to stimulate modifications to the structural organization
of the arterial wall by promoting elevated arterial distensibility, compliance and reduced
stiffness (134). However, the majority of the available literature focuses on the effects of
AT on arterial stiffening in males, where AT has consistently shown to produce
significant reductions in aortic PWV, AIx, and CAC in this population (196).
Although women have been underrepresented within the literature, recent
evidence suggests that AT may be able to manage arterial stiffening in females as well.
For example, Moreau et al. (164) investigated the effects of regular aerobic exercise, HRT,
and their influence on CAC in three groups of healthy, postmenopausal women using a
combination of cross-sectional (N=69; personal preference of exercise) and intervention
(N=12; walking intervention) studies. In the cross-sectional study, 69 participants were
segregated into three groups; 20 sedentary, no HRT (63 ± 2 years); 24 sedentary, on HRT
(61 ± 2 years); 14 AT, not taking HRT (64 ± 3 years); and 11 sedentary premenopausal
controls (28 ± 1 years). CAC, was lower (P < 0.001) in the postmenopausal compared to
premenopausal women, regardless of their level of physical activity or use of HRT.
However, among the postmenopausal subcategories, CAC was 33-43% higher in the
sedentary HRT and AT groups than in the sedentary, estrogen-deficient peers (P < 0.05).
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Furthermore, there were no significant differences between CAC of the sedentary HRT
and AT groups, and qualitatively similar findings were observed for ß-stiffness and DC
between groups. Taken together, these findings suggest that either aerobic exercise
training, HRT, or a combination of both can improve arterial stiffening by means of
elevated CAC in postmenopausal women.
In the intervention study, the arterial characteristics were evaluated in 12
sedentary postmenopausal women who were using HRT following a 12-week walkingbased AT regimen. The home-based exercise intervention consisted of 40 ± 2 minutes
per day bouts of walking at 70±1% of their age-determined HRmax. Following the
completion of the AT program, CAC and DC increased by ~ 40%, while ß-stiffness
decreased by ~ 25% (all P < 0.05). Furthermore, the absolute values for CAC, DC, and
ß-stiffness were higher than those observed in the sedentary HRT and AT groups that
were obtained from the cross-sectional portion of the study (P < 0.05), and were found to
improve to levels that mirrored that of the premenopausal women (P = 0.24). Taken
together, the results suggest that both HRT and habitual aerobic exercise have beneficial
effects on CAC, and a short-term aerobically-based exercise intervention can reverse the
age-related reduction in CAC in HRT-supplemented postmenopausal women, however,
the mechanism(s) responsible for this effect remain equivocal (171).
Sugawara and colleagues (180) investigated the effects of low (40% HRR) and
moderate (70% HRR) intensity cycle ergometry-based AT programs (3-5 times per week,
12 weeks at intensities corresponding to 180-300 kcal of energy expenditure) on CAC in
postmenopausal women (N=15, 59 ± 6 years). CAC and DC significantly increased posttraining in both the low and moderate intensity exercise groups (all, P < 0.05), however,
these improvements were not significantly different between the exercise intensities if the
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energy expenditure between the protocols is similar (P < 0.05).
Exercise-induced improvements in CAC can be mediated through modifications
in the expression of various vascular structural and functional factors, such as collagen,
elastin, ROS, and NO (134;177). Long-term AT can reduce and even reverse the progression
of age-related arterial stiffness (75;134;164;197). AT also mediates improvements in the
functional responsiveness of the vasculature and arterial compliance by stimulating
elevations in the expression of vasoactive genes and their products (198). Furthermore,
these aerobically-mediated improvements in CAC occur independent of reductions in
traditional CVD risk factors, solidifying the notion that AT reduces overall arterial
stiffness (75;164).
Dynamic Strength (Resistance) Training
The majority of the studies investigating the effects of RT on arterial stiffness
indices have thus far dealt with male participants (72-74;199-201), leaving a large proportion
of the female population without representation. The studies focusing on males have
provided the most controversial evidence for the effects of RT on arterial compliance,
where some have found improvements (199), reductions (72;73;201), or no changes in CAC,
arterial structural dimensions, or other stiffness indices in both younger (74) and older
males (200).
In contrast, recent evidence has provided consistent support for the potential of
RT to improve arterial stiffness in female populations. For example, Fjeldstad et al. (202)
investigated the effect of lower body RT (2-3 sets of 8 reps at 80% 1RM, 3 times per
week for 12 weeks) on small and large arterial compliance in healthy, premenopausal
women (N=32; RT: 33.2 ± 2.1 years, control: 36.8 ± 3.2 years). The authors found no
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changes in HR, PP, systemic vascular resistance, total vascular impedance or small
arterial compliance, while observing a significant time effect for improvements in large
artery compliance following the 12-week intervention among the trained and control
groups. As these improvements were observed in both groups, the changes cannot be
attributed to RT. However, in contrast to previous studies that identified reductions in
CAC following RT, no reductions were observed in this female population (202).
It has been postulated that exercises which incorporate a combination of both AT
and RT could provide the appropriate stimulus to facilitate improvements in CAC. This
was investigated by Cook et al. (203) who examined and compared the CAC of habitual
rowers (a unique exercise that encompasses aerobic and resistance training components)
to a sedentary control group (N=30; 50 ± 9 years) matched for age, body mass, metabolic
risk factors, sodium intake and BP, finding elevated CAC and reduced β-stiffness
amongst the rowers (rowers; 0.16 ± 0.01 mm2/mmHg versus control; 0.10 ± 0.01
mm2/mmHg, P < 0.001). Most recently, Figueroa et al. (204) investigated whether
combined long-term RT and AT circuit training can reduce arterial stiffness and MAP in
postmenopausal women (N=24; 57.5 ± 11 years). Participants were randomized to a
control (n=12) or exercise intervention group (n=12), where the exercisers participated in
circuit RT followed by moderate intensity (60% age-determined HRmax) AT 3-times per
week, for 12-weeks. SBP, DBP, MAP, HR, brachial artery PWV, and dynamic and IHG
strength were determined pre- and post-intervention. The exercise intervention produced
significant reductions in all of the measured haemodynamic variables (SBP, DBP, MAP,
HR), and baPWV (-0.8 ± 0.2 metres/sec), while improving IHG strength (2.8 ± 0.7 vs -0.6
± 1.2 kg). The authors conclude that the combined RT and AT circuit training program
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improves muscular strength, haemodynamics, and arterial stiffness in previously
sedentary, postmenopausal women.
Although the findings in males are equivocal, consistent improvements in CAC
have been observed in female populations following AT, RT, and a combined aerobic and
RT exercise modality. Taken together, these observations suggest that simultaneously
performed endurance training may negate the potential stiffening effects of strength
training, and the potential exists for beneficial arterial functional responses to RT when it
is performed across intensities (199;204).
Isometric Training
The effect of isometric exercise training on arterial compliance has received very
little attention in the literature. However, as noted above, AT, RT, and an AT/RT
combination have been found to improve CAC and isometric strength in in women
(180;204)

, and other female populations with CVD or who are at risk of developing such

diseased states (205).
Although currently equivocal, IHG-mediated reductions in resting BP are thought
to occur as a result of neurohumoral, structural, and/or functional modification to TPR
following exercise training (118), where improvements in CAC have been suggested as a
centrally-acting mechanism that could augment carotid baroreceptor sensitivity, lower
TPR, and ultimately facilitate the IHG-mediated reductions in resting BP.

1.6 Summary of Background
As noted in Section 1.1., CVD is the leading cause of death in Canadian women
(4)

, where elevated arterial BP (HT; ≥120/80 mmHg) greatly increases CVD risk (6;8).

Although the imporance of maintaining a healthy BP is well known, many older women
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do not have resting BP vaules controlled to within target range (119;120). IHG training is
effective in reducing BP in adults, and appears particularly effective in older women.
Despite these encouraging findings:
•

Most IHG training studies conducted to date are small

•

Women have been under-represented within the IHG literature, and

Furthermore, the mechanisms responsible for the IHG-mediated reductions in resting BP
remain elusive, yet improved CAC has been suggested as a centrally-acting mechanism
that could facilitate the post-training hypotensive response (132).
Therefore, investigating the effects of IHG training on various indices of
cardiovascular health (resting BP and CAC) among postmenopausal women who are at an
elevated risk of experiencing HT-related CVD (resting BP ≥ 120/80 mmHg) is warranted.

1.7 Thesis Objectives
The primary aim of the proposed study was to examine the effects of IHG training on:
1. Resting BP, and
2. To examine the effects of IHG training on CAC.

1.8 Specific Hypotheses
1. IHG training will lower resting BP, and
2. Increase CAC.
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Chapter 2: The effects of isometric handgrip training on carotid arterial compliance
and resting blood pressure in postmenopausal women

Manuscript
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2.1 Introduction
Cardiovascular disease (CVD) is the second most prominent cause of death
among Canadians, accounting for ~30% of the national deaths each year (1). The relative
risk of developing CVD in Canadian women increases four-fold following the transition
into menopause (2), and approximately 80% of all CVD-related mortality is associated
with arterial dysfunction and/or disorders (3). Elevations in arterial stiffness (measured by
the determination of arterial stiffness indices, such as carotid arterial compliance; CAC)
occur with increasing age (4;5), and elevated arterial blood pressure (BP) (6;7). In older
women this pathology is particularly concerning, as the process is primarily localized
within the large, elastic central arteries (e.g. the carotid) and is correlated with
hypertension (HT) and risk of myocardial infarction, heart failure, and cardiovascularrelated mortality (8).
The Public Health Agency of Canada considers sustained HT as one of the most
important primary risk factors associated with the development of CVD (9). HT afflicts
over 7.2 million Canadians (9), where half of those afflicted lie within the 55-74 years of
age range. By the 6th decade of life, the decade coinciding with menopause (10), the
prevalence of HT in women exceeds that of men (9). Furthermore, recent evidence has
identified a positive relationship between resting BP (BP) and CVD-risk occurring with
elevations in systolic blood pressure (SBP) by an increment of 20 mmHg or diastolic
blood pressure (DBP) by an increment of 10 mmHg within the range of 115/75mmHg to
185/115 mmHg for individuals between the ages of 40 and 70 years (9). This is
particularly concerning for postmenopausal women, as ~39% are pre-HT (11).
Prevention and treatment recommendations for elevated BP include lifestyle
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modifications, such as exercise prescription (12). The weight of the evidence suggests that
aerobic and resistance exercises effectively reduce resting BP and improve associated
cardiovascular pathologies (12). More specifically, aerobic training (AT) has been found
to reduce resting BP and arterial stiffness in young (13), elderly (14), normotensive (4), and
HT individuals (15). AT has been found to improve CAC in postmenopausal females
regardless of hormone-replacement therapy status (4), where the age-associated reductions
in CAC were ~50% less dramatic in AT women than in the age-matched sedentary
controls. More recent work has found improvements in arterial stiffness (observed
through reductions in brachial artery pulse wave velocity) and isometric forearm muscle
strength in postmenopausal women following 12 weeks of combined aerobic and
resistance circuit training (16). Resistance training (RT) can elicit reductions in resting BP
by ~3 mmHg, (17;18) and has also been incorporated within BP management programs.
Although the evidence surrounding RT and arterial stiffening in men is controversial,
increased CAC has been observed in postmenopausal rowers (a unique exercise that
encompasses AT and RT components) (19), and independently following AT, RT, and a
combined AT/RT exercise modality (20) when compared to sedentary controls. These
collective works suggest that the effects of RT preformed at multiple intensities and
modalities on CAC and arterial stiffness in postmenopausal women are most beneficial
when performed in conjunction with AT (16;19;20).
Despite the well-known ability of regular exercise to reduce resting BP across
populations, women are less likely than men to be consistently physically active and this
trend worsens as women age (21-23). A 2011 Health Report highlighting physical activity
trends amongst Canadians reinforces this statistic, reporting that only 14% of women are
meeting the currently suggested physical activity recommendations (22). Furthermore, >
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60% of women aged 60 years and above perform little or no sustained physical exercise
(21;24)

, and for those who initially do, adherence to the exercise programs drops by up to

~50% after the initial 6 months of participation (22;25). Therefore, facilitating women’s
participation in physical activity at levels that are sufficient to provide the associated
health benefits is a significant concern.
Isometric handgrip (IHG) training (4, 2 minute sustained contractions, separated
by a timed rest period, performed for a minimum of 3 times per week for up to 10 weeks)
is a novel and time-efficient form of exercise training, that has shown, through various
small proof-of-concept investigations, to lower resting BP in HT (26-29), and normotensive
(29-31)

individuals. A recent meta-analysis concluded that IHG-mediated reductions in

resting BP appear to occur to a similar, if not greater, degree than those facilitated by AT
(29)

. Additionally, individuals with higher initial resting BP experience greater post-IHG

BP reductions (27). To date, women have been underrepresented in the IHG literature, yet
available evidence suggests that older women have more pronounced post-IHG training
reductions in resting BP than their age-matched, male counterparts (32). Taken together,
this work suggests that older women with elevated resting BP may receive the greatest
benefit from the IHG intervention. Although the mechanisms associated with the IHGmediated reductions in resting BP are currently unknown, it has been suggested that
improved CAC may play a role (27). To date, no data is available on the effects of IHG
training on CAC. With age and/or chronic elevations in Resting BP, the elastic nature of
the vasculature is diminished and the central arteries are no longer able to effectively
buffer the pulsatile output of the heart (33). The resultant progressive elevation in SBP and
reduction in DBP facilitates an increase in arterial pulse pressure (PP), which initiates
increases in arterial wall thickness in attempts to normalize arterial wall stress (34). Stiffer
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large arteries like the carotid artery are associated with the increased prevalence of
isolated systolic HT in postmenopausal women and may partially explain the accelerated
rates of established CVD within this population (35). Improvements in CAC could
facilitate the appropriate modifications to total peripheral resistance that would stimulate
elevated cardiovagal baroreceptor sensitivity (19;36), thereby modulating the main neural
pathway for acute BP regulation which could effectively reduce resting BP (37). As
mentioned above, women appear to more consistently respond to traditional exercise
training with improved CAC, suggesting that it may be a viable mechanism of improved
BP regulation with IHG training (27), as well as a stand-alone cardiovascular benefit of
this training modality.
The purpose of this, randomized controlled, parallel-design study (superiority
trial) (38;39) is to investigate the effects of IHG training on CAC in Canadian women who
are at an elevated risk for developing HT-related CVD: postmenopausal women with
above normal resting BP (SBP ≥120 and/or DBP >80 mmHg) (40). The secondary
purpose is to replicate the previously observed reductions in resting BP amongst this
population. As an exploratory hypothesis, it is expected that the IHG training will
improve CAC in a postmenopausal population. It is further hypothesized that reductions
in resting BP will be observed following IHG training, thus implicating improved CAC as
a mechanism involved with the resting BP attenuation that occurs in response to IHG
training among postmenopausal women.
Confirmation of these collective hypotheses will provide the first evidence to
support IHG training as a viable method to improve CAC, a prominent HT pathology and
independent CVD risk-factor, in women at risk for developing CVD (post-menopausal
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women with higher than normal BP), while implicating it as a mechanism of reduced
resting BP post-IHG training.

2.2 Methods
Study Participants
Eight non-smoking post-menopausal women (amenorrheic for > 1 year) with
higher than normal resting BP (SBP ≥ 120 mmHg), were recruited for this two-site study
(University of Windsor, Windsor, ON and McMaster University, Hamilton, ON).
Exclusion criteria included: a recent medication change (< 1 month), recent
hospitalization (< 3 months), hormone replacement therapy, diabetes, autonomic
neuropathy, premature ventricular contractions, a paced heart rhythm at rest, heart failure,
CVD and those who have any physical limitation which would prevent them from safely
and/or effectively performing the IHG exercise.
Study Design
After inquiring about the study, interested individuals were scheduled to meet
with study investigators in their city of origin at either i) the Physical Activity and
Cardiovascular Research (PACR) lab (Room #240, Kinesiology Building, University of
Windsor) or ii) the Vascular Dynamics (VDL) Laboratory (Room #E103 Ivor Wynne
Centre, Department of Kinesiology, McMaster University) in order to obtain consent
(Appendix K & M) and to determine initial eligibility via a self-administered medical
questionnaire (Appendix N). Eligible individuals were then required to obtain their
health-care provider support prior to enrollment in the study via a physical activity
readiness medical examination questionnaire (Appendix O) and a physician-directed
letter of information (Appendix P & Q). After health care provider consent was
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obtained, each individual was familiarized to all testing procedures (41) and scheduled for
baseline testing.
Testing Protocol
The testing protocol included 2 series of independent resting BP measurements
(performed to initially determine eligibility) followed by a single cardiovascular testing
day. To minimize the influence of external factors on the cardiovascular measurements,
participants were asked to refrain from the consumption of alcohol or the participation in
vigorous exercise for 24 hours prior to each testing session and to avoid caffeine
consumption for 12 hours prior (41). All testing was conducted at least 4-hours postprandial, in a quiet, temperature-controlled room (23.5°C ± 1.3°C), and at the same time
of day (12:00 ± 2.1 hours). In order to minimize the effects of bladder distension on
resting BP measures, all participants were asked to void their bladder prior to each testing
session (41;42). All participants were tested at baseline (week 0) and upon completion of
the IHG training intervention (week 9).
Testing Day 1 & 2 (approximately 30 minutes per visit, separated by at least 24
hours): Each participant was assessed after 10-minutes of seated rest, where was
measured 4 times (Dinamap Carescape v100, Critikon, Tampa, Florida, USA) in the
brachial artery of the left arm, with 2-minutes between each measurement. The last 3
values obtained were averaged on each day to determine their eligibility (BP ≥ 120/80
mmHg for two days, separated by at least 24 hours) (43).
Testing Day 3 (approximately 2 hours): First, in order to account and control for
potential emotional or psychological influences on the measured physiological variables,
eligible participants were required to complete the State-Trait anxiety inventory (STAI-S
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and STAI-T) in isolation (44). These two, 20 item questionnaires allows for a tangible,
daily and self-reported anxiety score that can represent the potential impact of anxiety on
BP regulation (45). Following the completion of the STAI questionnaire, participants
underwent a battery of cardiovascular tests. All of the latter procedures employed were
performed in the supine position.
CAC was assessed using standardized testing and analysis procedures (46-49).
Briefly, resting BP was recorded from the brachial artery after 10-minutes of supine rest
using an automated oscillometer (Dinamap Carescape v100, Critikon, Tampa Florida,
USA) in order to calibrate the applanation tonometer. Continuous pulse pressure
waveforms were subsequently acquired for 1-minute from the right common carotid
artery with an applanation tonometer (Millar SPT-301, Millar Instruments, Inc., Houston,
Texas, USA), concurrent with the collection of carotid arterial diameters from the left
common carotid artery using B-mode ultrasonography (Vividi, GE Healthcare, Pittsburg,
Pennsylvania, USA) (48;50;51). A longitudinal image of the cephalic portion of the left
common carotid artery was obtained 1-2 cm distal to the carotid bulb (48;50;51) and used for
analysis. Recordings were obtained for 1-minute, where arterial diameters were
measured leading-edge to leading-edge (48) throughout the cardiac cycle using automated
edge-detection software and averaged for analysis. CAC was subsequently determined
using the following equation:
CAC = [π(Dmax/2)2 – π(Dmin/2)2]/ΔP

(Equation 1)

where ΔD is the change in arterial diameter from systole (Dmax) to diastole (Dmin), and ΔP
is the tonometrically-obtained arterial PP (48;50;51). All ultrasound images were obtained
from the same portions of the carotid artery using anatomic land-marking to ensure
accurate comparisons over time. All diameter measurements were made by the same
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ultrasonographer using custom-designed, automated-edge detection software (described
above) to minimize observer bias. In the current study, the intra-observer reproducibility
of CAC assessed was 1% (coefficient of variation) (Appendix C).
To better isolate improved CAC as the potential mechanism mediating reductions
in resting BP following IHG training, cardiac output (Q) was assessed using
echo/Doppler ultrasonography according to standardized published procedures (48;52;53).
Briefly, following at least 10 minutes of supine rest, the aortic root diameter (ARD) was
obtained from the parasternal long-axis view using B-mode ultrasonography with a
phased-array probe (3S RS, GE Healthcare, Pittsburg, Pennsylvania, USA) placed to the
left of the sternum in the third or fourth intercostal space. Images were measured using
electronic calipers that were positioned over the interior edges of the aortic wall
echocardiogram. ARD was measured at peak systolic and end diastole over 3 consecutive
heart cycles and used for the calculation of ARD using the following equation:
ARD = 1/3 Sd + 2/3 Dd

(Equation 2)

where Sd is the peak systolic arterial diameters and Dd is the end diastolic arterial
diameter. Variance in ARD measures of ≤ 1 mm was ensured and is considered
acceptable when attempting to assure accurate ARD assessment (54).
Aortic timed velocity integral (TVI) was then transcutaneously obtained for 1minute from the ascending aorta using a continuous-wave Doppler transducer (P2D RS,
GE Healthcare, Pittsburg, Pennsylvania, USA) placed within the suprasternal notch. The
orientation of the probe was manually manipulated in order to obtain the blood velocity
profile of the ascending aorta (the highest observed profile concomitant with the
perception of rapid onset and cessation of flow and minimal diastolic flow) (54). The
Doppler-derived strove volume (SV; mL) was then calculated according to the following
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equation (52):
SV = ARD2 · (0.785 · TVI)

(Equation 3)

and Q (L/min) was subsequently calculated using the following equation:
Q = (HR · SV)/10-3

(Equation 4)

where, HR was the average supine HR recorded during the aortic TVI assessment. To
ensure accuracy of the non-invasive determination of Q, the diameter and velocity
measures must be obtained from the same location. It can be assumed that the highest
systolic aortic velocity will be observed at the level of the narrowest aortic diameter (54),
hence, aortic velocity profiles were obtained after observing the highest aortic blood flow
velocity while ARD was measured at the most narrow location within the aortic root.
This non-invasive determination of Q is reproducible and highly correlated with the
thermodilution catheterization technique (UltrasoundQ = 0.98thermodilutionQ + 0.17;
r=0.96, N=105), allowing for the use of this non-invasive method for the direct
determination of Q without the use of any correction factors (54).
All signals were sampled at a frequency of 200 Hz, with the exception of the ECG
signal (1,000 Hz), and a data acquisition board was used for analogue to digital signal
conversion (Powerlab ML 870/P, AD Instruments, Colorado Springs, Colorado, USA) for
off-line beat-to-beat analysis, where applicable. All data was acquired and analyzed by
the same trained investigator. Measurements were analyzed using LabChart Pro 7 for
Windows (AD Instruments, Colorado Springs, Colorado, USA) or automated edgedetection software (Artery Measurement System v2.0, Chalmers University, Göteborg,
Sweden), where applicable.
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Randomization
Following baseline testing, participants were randomized through stratification by
study site (55). The randomization package for each site was identically constructed,
where manually generated blocks of 4 and 6 were compiled, ordered and randomly
stacked. Next, a unique identifier was labeled on the front of each envelope (eg. 1-W for
the 1st participant randomized at the University of Windsor; 1-M for the 1st participant
randomized at McMaster University), and subsequently placed in numerical order in a
locked filing cabinet until randomization was required. The associated paper was
shredded and the empty envelope was stapled to the participants intake file and stored in a
locked filing cabinet.

IHG Training Protocol
Following baseline testing, all participants trained 3 times per week, for a total of
8 weeks (26;28;32;43;56). Participants were instructed to record any changes in their exercise,
nutritional, and medication status in an exercise log at the onset of every exercise training
session. Participants randomized to the IHG-training group completed a bout of IHG
exercise: performing 4, 2 minute isometric contractions at 30% of their maximal
voluntary contraction (MVC; determined at the onset of each exercise session via
electronic linear load cells), using alternate hands with a 1-minute rest period between
contractions, on a programmed handgrip dynamometer (ZonaPLUS, Zona HEALTH,
Boise, Idaho, USA). Participants who were randomized to the sham-training control
group completed a similar bout of IHG exercise, however, at 3% MVC (ZonaPLUS, Zona
HEALTH, Boise, Idaho, USA).
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Statistical Analysis
Data was analyzed using two-way ANOVA (group x time) for CAC and its
associated variables (average carotid diameter, carotid PP), resting BP (SBP, DBP, mean
arterial BP; MAP [calculated as 1/3 SBP + 2/3 DBP], and brachial PP; [calculated as SBP
– DBP]), and Q (ARD, SV, supine HR), with Tukey’s post hoc procedures used to
evaluate specific differences between means, where applicable. Data analysis was
completed using IBM SPSS (PASW) Statistics v20 (SPSS Inc., Chicago, IL, USA).

2.3 Results
Participant baseline characteristics are displayed in Table 1. All participant
baseline characteristics were similar between the IHG training and the sham-trained
control groups (all P > 0.05). All participants in the IHG training group completed 24
IHG exercise sessions over the 8-week intervention period. There were no reported longterm changes in exercise, diet, and medication status throughout the investigation in either
the IHG training or sham-trained control groups.
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Table 1. Participant baseline characteristics
Characteristics
Age (years)
Height (cm)
Weight (kg)
BMI (kg/m2)
Resting SBP (mmHg)
Resting DBP (mmHg)
Resting MAP (mmHg)
Resting HR (beats·min-1)
State-Anxiety (score/80)
Trait-Anxiety (score/80)
Medication Classification (#)
ACE Inhibitor
Β-blocker
Calcium channel blocker
Diuretic
ACE inhibitor + Β-blocker
ACE inhibitor + Calcium channel blocker
ACE inhibitor + Diuretic

IHG Training
(n = 5)
67 ± 5
160 ± 3
70 ± 18
27 ± 7
138 ± 12
72 ± 5
92 ± 6
66 ± 7
50 ± 5
48 ± 3

Sham-trained Control
(n = 3)
62 ± 7
162 ± 9
74 ± 8
29 ± 6
142 ± 22
82 ± 16
101 ± 18
68 ± 5
51 ± 6
50 ± 4

1
0
0
2
0
0
1

0
0
1
0
0
0
0

BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure;
MAP, mean arterial pressure; HR, heart rate; ACE, angiotensin converting enzyme.
Values are mean ± SD.

Effects of Isometric Handgrip Training on Carotid Arterial Compliance, Diameter
and Pulse Pressure
IHG training produced no significant changes in CAC, carotid arterial diameters,
or pulse pressures (Figure 1). Specifically, CAC remained unchanged within the IHG
(0.07 ± 0.01 mm2/mmHg to 0.06 ± 0.02 mm2/mmHg) and sham-trained control (0.06 ±
0.02 mm2/mmHg to 0.07 ± 4.0 x 10-3 mm2/mmHg) groups (P = 0.23). Similarly, average
carotid arterial diameters (IHG; 6.36 ± 0.62 mm to 6.29 ± 0.74 mm versus sham-trained;
7.12 ± 0.74 mm to 7.01 ± 0.82 mm) and PP (IHG; 46.61 ± 13.98 mmHg to 46.87 ± 17.49
mmHg versus sham-trained; 57.20 ± 3.18 mmHg to 62.57 ± 14.44 mmHg) remained
unchanged following the training period (P = 0.75 and P = 0.52, respectively).
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Furthermore, reductions in SBP were not correlated with improvements in CAC
following the IHG intervention [F(1,4) = 0.569, P = 0.317].
Fig 1.
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Fig 1. Effects of 8-weeks of isometric handgrip (IHG) training on (a) CAC, (b) carotid
arterial PP, and (c) diameter between the IHG (30% MVC) and sham-training (3% MVC)
interventions. Values are means ± SD.
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Effects of Isometric Handgrip Training on Resting Blood Pressure
IHG training produced no significant changes in resting systolic BP, diastolic BP,
MAP or brachial PP (Figure 2). Specifically, systolic BP remained unchanged within the
IHG (138 ± 12 mmHg to 128 ± 18 mmHg) and sham-trained (142 ± 22 mmHg to 138 ±
16 mmHg, P = 0.47) groups. Diastolic BP was also unchanged (IHG; 72 ± 5 mmHg to
68 ± 6 mmHg versus Sham-trained; 82 ± 16 mmHg to 75 ± 16 mmHg, P = 0.22).
Furthermore, IHG training resulted in no significant changes in MAP (IHG; 92 ± 6
mmHg to 88 ± 6 mmHg versus Sham-trained; 102 ± 18 mmHg to 96 ± 16 mmHg, P =
0.77) or brachial PP (IHG; 66 ± 7 mmHg to 60 ± 8 mmHg versus Sham; 62 ± 9 mmHg to
63 ± 10 mmHg, P = 0.24).
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Fig 2. Effects of 8-weeks of isometric handgrip (IHG) training on resting (a) SBP,
systolic BP; (b) DBP, diastolic BP; (c) MAP, mean arterial pressure; and (d) Brachial PP
between the IHG (30% MVC) and sham-training (3% MVC) interventions. Values are
means ± SD.

Effects of Isometric Handgrip Training on Anxiety and Cardiac Output
IHG training produced no significant changes in state- and trait- anxiety scores in
either the IHG or sham-trained groups (all P > 0.05). Furthermore, Q and its associated
indices (Table 2) remained unchanged with IHG training (all P > 0.05).
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Table 2. Measures of cardiac output, pre- to post-intervention
Group

Pre-intervention
HR
(beats*min-1)

(mL*heart beat-1)

(L*min-1)

IHG
Sham

60.97 ± 11.32
63.62 ± 6.53

75.00 ± 11.56
63.55 ± 13.14

4.52 ± 0.86
3.99 ± 0.43

SV

Q

Post-intervention
HR

SV

Q

(beats*min-1)

(mL*heart beat-1)

(L*min-1)

60.64 ± 9.59
64.01 ± 7.28

80.03 ± 19.76
66.04 ± 7.28

4.78 ± 1.05
4.21 ± 1.20

HR, heart rate; SV, stroke volume; Q, cardiac output. Values are mean ± SD.

2.4 Discussion
Women have been underrepresented in the IHG literature, yet available evidence
suggests that older women with elevated resting BP may receive the greatest benefit from
this unique form of exercise training. Although the mechanisms associated with the IHGmediated reductions in resting BP are currently unknown, improved CAC has been
proposed as a likely mechanism within this population (27).
The current work is the first prospective, randomized controlled IHG trial to
examine the effects of training on arterial compliance while also employing a shamtraining intervention as a control group in a population believed to benefit the most from
IHG exercise. This work is noteworthy, as investigating the influence of IHG on CAC
within this population is essential; in addition to its potential to facilitate BP reductions
post-training, its improvement may reduce a women’s overall CVD risk independent of
any BP lowering benefit. Second, the use of a sham-training (3% MVC) control group
versus a non-exercising control group is important as it attempts to account for a potential
placebo effect of the IHG training. Furthermore, as the lowest exercise intensity that can
produce significant physiological changes following IHG training has yet to be
determined (31), it may serve to inadvertently identify this intensity.
In contrast to the collective hypotheses, 8-weeks of IHG training did not
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significantly improve CAC or reduce resting BP, in comparison to a sham-trained control
group, within this population of postmenopausal women with above normal BP.
Effects of Isometric Handgrip Training on Carotid Arterial Compliance
CAC did not change following the 8-week IHG intervention. In contrast to the
findings of the present study, previous work examining the effect of 12-weeks of aerobic
training on CAC (4;49) noted improvements at magnitudes of ~40% among
postmenopausal populations (N=12). However, the current observations are in
accordance with the works of Fjeldstad et al. (20), who observed no significant changes in
CAC in premenopausal women (N=21) following 12-weeks of RT in comparison to a
non-exercising control group (N=11). Despite the negative findings, the results of the
current study must be interpreted with caution due to the small sample size. The above
trials were powered to detect changes in CAC following exercise training, however, the
current study did not reach recruitment targets to sufficiently power this work (sample
size calculated as n=10 per group for changes in CAC at α = 0.05 and β = 0.2)(28;32).
Furthermore, a longer intervention period may also be required in order to identify
significant changes in CAC, as this trial utilized an 8-week intervention while the
majority of previous AT and/or RT investigations employed exercise interventions
spanning between 10 to 16 weeks (4;5;15;16;20;47-50;57-59). Adopting a longer training period
may produce significant improvements in CAC; however, these improvements may not
be associated with resting BP reductions. As many anti-HT medications are known to
improve arterial compliance (i.e., ACEIs and diuretics) (60), it cannot be ruled out that
those participants on HT pharmacotherapy may have received maximal CAC benefit prior
to enrolling in the study, thus lowering their capacity to respond to the IHG intervention
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with increases in CAC.
The lack of post-training improvements in CAC may also be attributed to the
lower stimulus magnitude versus more traditional AT and/or RT stimuli. For instance,
during aerobic exercise the continuous, progressive elevation in the pulsatile output of the
heart occurs at the appropriate intensity to stimulate modifications to the structural
organization of the arterial wall, promoting elevated arterial distensibility, compliance,
and reduced stiffness (60). As HR reaches, on average, maximal values of ~5 beats/minute
above rest during an IHG training bout (61-63) concomitant to subtle increases in Q (61), it
could be speculated that the IHG-mediated elevations in resting HR and/or Q are not
sufficient stimuli to facilitate training-induced structural modifications within the arterial
wall. In addition, as MVC did not significantly change in either then IHG or shamtrained groups (all P > 0.05), this exercise might not provide the required intensities to
stimulate arterial re-organizations that would be reflected through improved CAC.
Effects of Isometric Handgrip Training on Resting Blood Pressure
Reductions in resting SBP (10 mmHg), MAP (4 mmHg) and brachial PP (5
mmHg) were observed within the intervention group following 8-weeks of IHG training.
Although the observed reduction in SBP exceeds the average reported among IHG
trainers following an 8-week intervention (-5.7 mmHg) (27), the current observations were
not deemed statistically significant (P > 0.05). However, the IHG-mediated reduction in
SBP observed in the present study can be considered clinically significant, as reductions
between 2-5 mmHg are associated with a reduced risk of stroke (14%), coronary artery
disease (9%) (12) and all-cause mortality (7%) (64) within the general population. The
observations of the current study are similar to those of Stiller-Moldovan et al. (65) who
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noted clinically significant reductions in 24-hour, daytime, and nighttime SBP (2 mmHg,
2 mmHg, and 3 mmHg, respectively) following 8-weeks of IHG training in wellcontrolled medicated HT individuals.
It is important to note that individuals within the sham-trained intervention also
experienced reductions in SBP (4 mmHg), DBP (7 mmHg), and MAP (6 mmHg) that can
also be considered clinically significant. As this is the first trial to date to investigate the
effects of IHG training when performed at 3% MVC, it cannot definitively be determined
at this time whether there was a legitimate reduction in resting BP following such a low
intensity IHG intervention. Previous work has employed the use of a “sham”-trained
control group, however, the individuals simply held the handgrip dynamometer without
exhibiting any effort or force (31). Therefore, attempting to infer responses between the
observations obtained within this study from those obtained from Ray and Carrasco (31)
must be done with caution, as the labeling of the groups incites confusion between the
actual exercises performed (8 contraction minutes per day of IHG at 3% MVC, performed
3 times per week for 8 weeks, totaling 192 contraction minutes, versus 12 holding
minutes of IHG per day at 0% MVC, performed 4 times per week for 5 weeks, totaling
240 holding minutes). Others have also employed similar sham-trained (0.005% MVC)
groups within rhythmic isometric training studies, however, further inference cannot be
made as post-training BP was not assessed (66).
The lack of statistically significant changes in resting BP was not only contrary to
our hypothesis, but also to the majority of published IHG studies in individuals with
above normal BP over a 5- to 8-week training period (26-28;67;68), including those medicated
for HT. However, the data in medicated HT is equivocal, with some noting post-IHG
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training reductions in resting BP (26;27), while others have not (62;65). Why were there no
post-training reductions in resting BP? Unfortunately, as with CAC, the current study
was not sufficiently powered to detect statistically significant post-training reductions in
resting BP: sample size calculated as n=12 per group for reductions in resting BP at α =
0.05 and β = 0.2 (28;30;31).
However, the use of different HT pharmacotherapies among research cohorts
involving individuals medicated for HT may also explain these discrepant findings. ACE
inhibitors and diuretic therapy facilitate the downward resetting of the HR arm of the
baroreflex when managing BP (69;70), thus minimizing the potential for IHG-training
induced improvements. However, this confounder is likely negligible in the current
study, as a smaller proportion of individuals in the 2007 study conducted by McGowan et
al. (26) were receiving ACE inhibitor and/or diuretic therapy than those in the current
investigation (64% versus 80% IHG trainers).
The heterogeneous nature of the population in the current study, in that some and
not all were receiving medication to treat elevated BP, suggests that greater exposure to
the IHG stimulus may be required in order to induce statistically significant post-training
reductions in resting BP. Although improvements in resting BP have been observed in
medicated and non-medicated HT following training in as little as 8-weeks (26), the weight
of the evidence suggests that individuals medicated for HT may require as much as 10weeks of IHG training to elicit reductions in resting BP using the traditional 3 times per
week, 8-week training protocol (27;28;65). Taken together, this suggests that in
heterogeneous populations whereby some participants are on pharmacotherapy while
others are not, greater exposure time to the IHG stimulus may be required. This can be
accomplished by either increasing the per-week training frequency within an 8-week
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period, or through an extended total training time.
Although statistically nor clinically significant reductions in DBP were not
observed within the current study, these observations are in accordance with most (26;67),
but not all (68) IHG training studies involving individuals with elevated BP (medication
and non-medicated).
The evidence provided by this study further supports the effectiveness of IHG
training in reducing resting BP (clinical) among individuals who are at an elevated risk
for the development of CVD (65), however, future works with separate populations of
postmenopausal women (i.e., medicated and non-medicated), larger sample sizes, and/or
longer intervention periods are required to address this question.
Improved CAC as a Mechanism of BP Reduction following Isometric Handgrip
Training
Improved CAC has been suggested as a potential mechanism involved with the
post-IHG training reductions in resting BP (27). Although there were no statistically
significant reductions in resting BP with traditional IHG training at 30% MVC in the
current study, discussion of improved CAC as a mechanism responsible for post-training
resting BP attenuation is warranted, as there were clinically relevant reductions in BP
with IHG training performed at either 30% and 3% MVC. The findings of the current
study suggest that improved CAC is not a mechanism of resting BP reduction with IHG
training [F(1,4) = 0.569, P = 0.317], however, this must be interpreted with caution, as a
sufficiently powered investigation of the effects of IHG training on CAC may uphold this
hypothesis of benefit. However, the role of exercise intensity, and/or intervention length,
and/or medication in the lack of observed changes in CAC cannot be determined. As
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such, a large-scale, randomized controlled trial investigating the effects of IHG training
intensity and/or intervention length on CAC in medicated and non-medicated
postmenopausal women with above normal resting BP is warranted.
To date, the mechanisms associated with the IHG training-induced reductions in
resting BP remain elusive. Multiple plausible theories behind the post-IHG training BP
attenuations have been proposed in addition to improved CAC-mediated baroreflex
function, including: i) improvements in markers of oxidative stress (67), ii) reductions in
tonic sympathetic nerve activity (71), iii) modifications to autonomic functioning via
improved vagal control (28), iv) ischemia-reperfusion that may mediate improvements in
oxidative stress (72), and/or v) improved endothelial-dependent vasodilatory capacity via
increased systemic shear stress (73). Reductions in total peripheral resistance via one or
more of these mechanisms are likely responsible for post-IHG training BP reductions,
however, no published literature to date is available on the effect of IHG training on Q,
another important index of BP regulation across populations. In the present study, Q and
its associated indices (HR and SV) remained unchanged following the 8-week IHG
intervention period. This is in accordance with previous work by Spina et al. (74) who
investigated the cardiac functional adaptations and their association with improvement
cardiovascular fitness (VO2max) in response to a 9-12 month AT program in older,
individuals (N=31; 16 females, 64 ± 3 years) with above normal BP (AT: SBP, 129 ± 3
mmHg; DBP, 84 ± 2 mmHg versus Control: SBP, 130 ± 5 mmHg; DBP, 84 ± 5 mmHg).
The investigators noted a sex-based difference in the cardiovascular adaptations to
training, where training-induced improvements in VO2max were driven by elevations in
resting SV in men, while improvements within the female participants were the result of
enhanced arterial-venous O2 extraction (74). These observations are in accordance with
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others who have also noted a lack of change in Q following a 26-week RT or AT
intervention amongst older men and women (N=57; 72 ± 3 years) with normal or elevated
BP (75). As such, reductions in resting Q are not typically expected in women with above
normal BP following exercise training, thereby implicating training-induced reductions in
total peripheral resistance as the primary mechanism that is responsible for reductions in
resting BP in this population (8).

2.5 Limitations
The results of the current investigation are novel and note-worthy, however,
several limitations do exist. The lack of detected significance may certainly lay within
the small sample size in the present study (N=8), as sample size calculations based on
either: i) elevations in CAC following an AT or RT intervention (49;59;76), or ii) reductions
in mean resting BP post-IHG interventions (28;30) estimated that 10 and 12 individuals per
group, respectively, would be required to detect statistical significance (α = 0.05, ß = 0.2).
Therefore, results must be considered with caution. Several participants were also being
medicated for HT, with a diversity of medication types between individuals. In order to
account for the hypotensive effect of medications on arterial function and BP all
medications were strictly monitored throughout the study period, and all medications had
been maintained for a period of greater than 4-months prior to the study period. This
could also be considered a strength of the current investigation, as this is more reflective
of individuals with above normal BP in the general population.

2.6 Perspectives
Older women stand to achieve the greatest benefit from IHG training, and
postmenopausal women with above normal BP are at increased risk of CVD
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development. Reduced CAC occurs as an intrinsic effect of aging and in response to
sustained HT; being identified as a prominent CVD risk factor among postmenopausal
women (35) and as a mechanism of BP reductions with IHG training.
This study, conducted in a small sample of postmenopausal women with above
normal BP, provides evidence of clinical reductions in BP rest following IHG training, a
finding which supports the use of IHG as an efficacious treatment method in the
management of elevated BP and may facilitate a reduced risk of CVD-related mortality
within this population. However, the primary hypotheses, that 8-weeks of IHG training
would produce statistically significant improvements in CAC concomitant with
statistically significant reductions in resting BP, were not upheld. Therefore, the use of
IHG training to reduce overall CVD risk by means of improvements in CAC can neither
be confidently supported nor refuted, nor whether improvements in CAC facilitate
reductions in resting BP. Future large-scale, randomized controlled trials designed to
investigate the effects of multiple IHG training intensities and/or intervention lengths on
CAC and resting BP is required to determine the differing influence of multiple exercise
protocols on these variables, and whether training-induced improvements in CAC are
associated with reductions in resting BP in multiple populations (i.e., medicated and nonmedicated HT).
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Participant Characteristics
ID

Group

1
2
3
4
5
6
7
8

IHG
IHG
IHG
IHG
IHG
Sham
Sham
Sham

Age
(years)
65
71
69
60
70
54
64
67

Height
(cm)
160
161
157
165
157
170
152
163

Weight
(kg)
67
102
57
63
61
70
83
70

BMI
(kg/m2)
26.2
39.4
23.1
23.1
24.7
24.2
35.9
26.3

Medication
Cholesterol
Cholesterol
Diuretic
Diuretic, ACEI
N/A
N/A
Cholesterol
CCB

BMI, body mass index; IHG, isometric handgrip; ACEI, angiotensin converting enzyme
inhibitor; CCB, calcium channel blocker; BB, beta blocker.
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Pre-training Maximum Voluntary Contraction
ID

Group

1
2
3
4
5
6
7
8

IHG
IHG
IHG
IHG
IHG
Sham
Sham
Sham

Maximum Voluntary Contraction
Right-hand
Left-hand
Average
58
60
52
50
47
49
55
54
55
55
60
69
70
66
68
43
58
51
48
45
47
49
63
56

IHG, isometric handgrip

Post-training Maximum Voluntary Contraction
ID

Group

1
2
3
4
5
6
7
8

IHG
IHG
IHG
IHG
IHG
Sham
Sham
Sham

Maximum Voluntary Contraction
Right-hand
Left-hand
Average
70
63
67
83
71
77
55
48
52
78
51
65
65
66
66
60
63
62
31
27
29
54
62
58

IHG, isometric handgrip
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Pre-training Carotid Arterial Characteristics
ID
1
2
3
4
5
6
7
8

Group
IHG
IHG
IHG
IHG
IHG
Sham
Sham
Sham

LDmax

LDmin

ARD

PP

CAC

(mm)

(mm)

(mm)

(mmHg)

(mm2/mmHg)

6.689
7.448
6.507
6.575
5.634
7.466
6.534
8.006

6.356
7.087
6.070
6.348
5.385
7.279
6.180
7.605

6.466
7.206
6.214
6.423
5.467
7.340
6.297
7.737

37.180
64.021
58.921
40.499
32.435
60.095
53.797
57.708

0.0916
0.0643
0.0732
0.0571
0.0665
0.0362
0.0658
0.0853

IHG, isometric handgrip; LDmax, maximum lumen diameter; LDmin, minimum lumen
diameter; PP, pulse pressure; CAC, carotid arterial compliance.

Post-training Carotid Arterial Characteristics
ID
1
2
3
4
5
6
7
8

Group
IHG
IHG
IHG
IHG
IHG
Sham
Sham
Sham

LDmax

LDmin

ARD

PP

CAC

(mm)

(mm)

(mm)

(mmHg)

(mm2/mmHg)

6.293
7.353
6.742
6.516
5.467
7.579
6.359
7.903

6.006
7.019
6.340
6.305
5.322
7.156
5.956
7.535

6.101
7.129
6.473
6.375
5.370
7.296
6.089
7.657

43.363
65.004
64.538
25.795
35.646
78.861
57.510
51.332

0.0639
0.0579
0.0640
0.0826
0.0345
0.0620
0.0678
0.0869

IHG, isometric handgrip; LDmax, maximum lumen diameter; LDmin, minimum lumen
diameter; PP, pulse pressure; CAC, carotid arterial compliance.
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Pre-training Resting Measures
ID
1
2
3
4
5
6
7
8

Group
IHG
IHG
IHG
IHG
IHG
Sham
Sham
Sham

SBP

DBP

MAP

HR

(mmHg)

(mmHg)

(mmHg)

(bpm)

145.5
154.6
133.3
122.8
133.6
167.0
126.4
132.7

72.5
63.9
71.5
75.7
78.0
100.19
76.4
69.2

96.6
93.8
81.9
91.2
96.3
122.2
92.9
90.2

68.7
58.2
76.2
64.7
63.6
66.7
74.4
63.9

IHG, isometric handgrip; SBP, systolic blood pressure; DBP, diastolic blood pressure;
MAP, mean arterial pressure; HR, heart rate; mmHg, millimetres of mercury; bpm, beats
per minute

Post-training Resting Measures
ID
1
2
3
4
5
6
7
8

Group
IHG
IHG
IHG
IHG
IHG
Sham
Sham
Sham

SBP

DBP

MAP

HR

(mmHg)

(mmHg)

(mmHg)

(bpm)

138.9
147.3
134.3
119.1
102.2
155.7
123.1
137.6

72.8
62.1
63.3
75.2
66.7
92.5
62.4
69.6

94.6
90.2
86.8
89.7
78.5
113.4
82.5
92.0

72.3
53.8
67.1
56.6
76.8
71.0
75.0
57.5

IHG, isometric handgrip; SBP, systolic blood pressure; DBP, diastolic blood pressure;
MAP, mean arterial pressure; HR, heart rate; mmHg, millimetres of mercury; bpm, beats
per minute
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Pre-testing Echocardiography and Cardiac Output
ID
1
2
3
4
5
6
7
8

Group
IHG
IHG
IHG
IHG
IHG
Sham
Sham
Sham

Vmax

TVI

Sd

Dd

ARD

SV

HR

Q

(m/s)

(cm)

(cm)

(cm)

(cm)

(mL)

(bpm)

(L/min)

1.173
1.284
1.081
1.101
1.042
1.062
1.209
1.119

24.405
25.629
22.905
24.747
28.137
21.474
22.229
29.786

2.25
2.16
1.94
2.17
2.00
2.38
1.93
2.19

1.97
2.04
1.69
1.87
1.77
2.04
1.64
1.99

2.062
2.080
1.770
1.966
1.844
2.152
1.735
2.057

81.49
87.01
56.35
75.06
75.08
78.08
52.50
60.07

72.34
52.87
72.86
58.97
47.81
57.42
70.45
63.00

5.895
4.600
4.106
4.427
3.590
4.483
3.698
3.784

Vmax, maximum stroke velocity; TVI, time velocity integral; Sd, systolic aortic root
diameter; Dd, diastolic aortic root diameter; ARD, aortic root diameter; SV, stroke
volume; HR, heart rate; Q, cardiac output.

Post-testing Echocardiography and Cardiac Output
ID
1
2
3
4
5
6
7
8

Group
IHG
IHG
IHG
IHG
IHG
Sham
Sham
Sham

Vmax

TVI

Sd

Dd

ARD

SV

HR

Q

(m/s)

(cm)

(cm)

(cm)

(cm)

(mL)

(bpm)

(L/min)

1.216
1.231
1.040
1.003
1.105
1.128
1.292
0.737

25.367
31.942
24.245
20.989
30.202
24.900
24.194
17.089

2.13
2.22
1.93
2.30
2.03
2.28
1.91
2.07

1.96
2.01
1.60
1.93
1.83
2.07
1.69
1.87

2.02
2.08
1.71
2.05
1.899
2.139
1.764
1.933

80.94
108.64
55.50
69.53
85.53
88.93
59.08
50.11

72.42
53.14
60.97
67.33
49.33
60.39
72.40
59.25

5.862
5.773
3.384
4.682
4.219
5.370
4.277
2.969

Vmax, maximum stroke velocity; TVI, time velocity integral; Sd, systolic aortic root
diameter; Dd, diastolic aortic root diameter; ARD, aortic root diameter; SV, stroke
volume; HR, heart rate; Q, cardiac output.
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State-Trait Anxiety Inventory for Adults Form Y-1 (State Anxiety) & Y-2 (Trait
Anxiety)

Pre-training
ID
1
2
3
4
5

Group
IHG
IHG
IHG
Sham
Sham

STAI-S
55
47
47
55
46

STAI-T
46
51
49
52
47

Post-training
STAI-S
47
49
48
62
41

STAI-T
46
55
49
47
46

IHG, isometric handgrip; STAI-S, state anxiety; STAI-T, trait anxiety
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Participant Baseline Characteristics
One-Way ANOVA: Baseline Age Between-Group Differences
1a. Age (Means)
Group
IHG
Sham

Mean
67.0
61.67

SE
2.02
3.93

N
5
3

1b. Age (All Effects)
ANOVA
Age
Sum of Squares
Between Groups

df

Mean Square

53.333

1

53.333

Within Groups

174.667

6

29.111

Total

228.000

7

F

Sig.

1.832

.225

One-Way ANOVA: Baseline Height Between-Group Differences
2a. Height (Means)
Group
IHG
Sham

Mean
160
161.67

SE
1.48
5.24

N
5
3

2b. Height (All Effects)
ANOVA
Height
Sum of Squares
Between Groups

df

Mean Square

5.208

1

5.208

Within Groups

208.667

6

34.778

Total

213.875

7

129

F

Sig.
.150

.712
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One-Way ANOVA: Baseline Weight Between-Group Differences
3a. Weight (Means)
Group
IHG
Sham

Mean
70
74.3

SE
8.16
4.33

N
5
3

3b. Weight (All Effects)
ANOVA
Weight
Sum of Squares
Between Groups

df

Mean Square

35.208

1

35.208

Within Groups

1444.667

6

240.778

Total

1479.875

7

F

Sig.
.146

.715

One-way ANPOVA: Baseline Body Mass Index Between-Group Differences
4a. BMI (Means)
Group
IHG
Sham

Mean
27.3
728.8

SE
3.08
3.60

N
5
3

4b. BMI (All Effects)
ANOVA
BMI
Sum of Squares
Between Groups

df

Mean Square

4.219

1

4.219

Within Groups

267.480

6

44.580

Total

271.699

7

130

F

Sig.
.095

.769
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One-way ANOVA: Baseline Systolic BP Between-Group Differences
5a. Resting Systolic BP (Means)
Group
IHG
Sham

Mean
138
142

SE
5.49
12.61

N
5
3

5b. Resting Systolic BP (All Effects)
ANOVA
SBP_BL
Sum of Squares
Between Groups

df

Mean Square

31.396

1

31.396

Within Groups

1558.828

6

259.805

Total

1590.224

7

F

Sig.
.121

.740

One-Way ANOVA: Baseline Diastolic BP Between-Group Differences
6a. Resting Diastolic BP (Means)
Group
IHG
Sham

Mean
72.3
81.9

SE
2.40
9.32

N
5
3

6b. Resting Diastolic BP (All Effects)
ANOVA
DBP_BL
Sum of Squares

Df

Mean Square

Between Groups

173.052

1

173.052

Within Groups

636.691

6

106.115

Total

809.743

7

131

F
1.631

Sig.
.249
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One-way ANOVA: Baseline Mean Arterial BP Between-Group Differences
7a. Resting Mean Arterial BP (Means)
Group
IHG
Sham

Mean
91.2
101.8

SE
2.70
10.24

N
5
3

7b. Resting Mean Arterial BP (All Effects)
ANOVA
MAP_BL
Sum of Squares

df

Mean Square

Between Groups

179.707

1

179.707

Within Groups

775.312

6

129.219

Total

955.019

7

F

Sig.

1.391

.283

One-way ANOVA: Baseline Brachial Artery PP Between-Group Differences
8a. Resting Brachial PP (Means)
Group
IHG
Sham

Mean
65.63
60.12

SE
7.55
5.16

N
5
3

8b. Resting Brachial PP (All Effects)
ANOVA
BrachialPP_BL
Sum of Squares
Between Groups

df

Mean Square

57.029

1

57.029

Within Groups

1299.434

6

216.572

Total

1356.463

7

132

F

Sig.
.263

.626
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One-way ANOVA: Baseline Resting Average Carotid Diameter Between-Group
Differences
9a. Resting Average Carotid Diameter (Means)
Group
IHG
Sham

Mean
6.36
7.12

SE
0.28
0.43

N
5
3

9b. Resting Average Carotid Diameter (All Effects)
ANOVA
CarotidARD_BL
Sum of Squares

df

Mean Square

Between Groups

1.110

1

1.110

Within Groups

2.657

6

.443

Total

3.768

7

F
2.506

Sig.
.164

One-way ANOVA: Baseline Resting Carotid Pulse Pressure Between-Group Differences
10a. Resting Carotid Pulse Pressure (Means)
Group
IHG
Sham

Mean
46.6
57.2

SE
6.25
1.83

N
5
3

10b. Resting Carotid Pulse Pressure (All Effects)
ANOVA
PP_BL
Sum of Squares

df

Mean Square

Between Groups

210.234

1

210.234

Within Groups

802.102

6

133.684

1012.335

7

Total

133

F
1.573

Sig.
.256
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One-way ANOVA: Baseline Resting Carotid Arterial Compliance Between-Group
Differences
11a. Resting Carotid Arterial Compliance (Means)
Group
IHG
Sham

Mean
0.061
0.062

SE
0.008
0.014

N
5
3

11b. Resting Carotid Arterial Compliance (All Effects)
ANOVA
CAC_BL
Sum of Squares

df

Mean Square

Between Groups

.000

1

.000

Within Groups

.002

6

.000

Total

.002

7

F

Sig.
.015

.905

One-way ANOVA: Baseline Resting Mean Average Aortic Diameter Between-Group
Differences
12a. Resting Average Aortic Diameter (Means)
Group
IHG
Sham

Mean
1.94
1.98

SE
0.06
0.13

N
5
3

12b. Resting Average Aortic Diameter (All Effects)
ANOVA
AoD_BL
Sum of Squares

df

Mean Square

Between Groups

.003

1

.003

Within Groups

.169

6

.028

Total

.172

7

134

F

Sig.
.091

.773
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One-way ANOVA: Baseline Supine Resting Heart Rate Between-Group Differences
13a. Supine Resting Heart Rate (Means)
Group
IHG
Sham

Mean
61.0
63.6

SE
5.07
3.77

N
5
3

13b. Supine Resting Heart Rate (All Effects)
ANOVA
Q_HR_BL
Sum of Squares
Between Groups

df

Mean Square

13.169

1

13.169

Within Groups

598.836

6

99.806

Total

612.005

7

F

Sig.
.132

.729

One-way ANOVA: Baseline Resting Stroke Volume Between-Group Differences
14a. Resting Stroke Volume (Means)
Group
IHG
Sham

Mean
74.997
63.55

SE
5.168
7.587

N
5
3

14b. Resting Stroke Volume (All Effects)
ANOVA
StrokeVol_BL
Sum of Squares

df

Mean Square

Between Groups

245.672

1

245.672

Within Groups

879.597

6

146.600

1125.270

7

Total

135

F
1.676

Sig.
.243
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One-way ANOVA: Baseline Resting Cardiac Output Between-Group Differences
15a. Resting Cardiac Output (Means)
Group
IHG
Sham

Mean
4.52
3.99

SE
0.384
0.248

N
5
3

15b. Resting Cardiac Output (All Effects)
ANOVA
Q_BL
Sum of Squares
Between Groups

df

Mean Square

.537

1

.537

Within Groups

3.312

6

.552

Total

3.849

7

136

F

Sig.
.972

.362
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Effects of IHG Training on Carotid Arterial Pulse Pressure and Compliance
Carotid Arterial Compliance Pre- to Post-IHG Training Repeated Measures ANOVA
1a. Carotid Arterial Compliance (Means)
Group
IHG
IHG
Sham
Sham

Time
PrePostPrePost-

Mean
0.071
0.061
0.062
0.072

SE
0.008
0.007
0.010
0.009

N
5
5
3
3

1b. Carotid Arterial Compliance (All Effects)

Carotid Average Arterial Diameter Pre- to post-IHG Training Repeated Measures
ANOVA
2a. Carotid Average Arterial Diameter (Means)
Group
IHG
IHG
Sham
Sham

Time
PrePostPrePost-

Mean
6.36
6.29
7.13
7.01

SE
0.298
0.315
0.384
0.407

2b. Carotid Average Arterial Diameter (All Effects)
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N
5
5
3
3
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Carotid Arterial Pulse Pressure Pre- to Post-IHG Training Repeated Measures ANOVA
3a. Carotid Arterial Pulse Pressure (Means)
Group
IHG
IHG
Sham
Sham

Time
PrePostPrePost-

Mean
46.61
46.87
57.20
62.57

SE
5.171
7.395
6.675
9.547

3b. Carotid Arterial Pulse Pressure (All Effects)

4a. Correlation Analysis (CAC and SBP)
Group
IHG

Variable
SBP

Sham

SBP

CAC
0.569
p=0.317
-0.866
p=0.333

N
5
3

138

N
5
5
3
3
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5a. Carotid Arterial Diameter Reproducibility

LDmax, maximum lumen diameter; LDmin, minimum lumen diameter; CV, coefficient of
variation
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Effects of IHG Training on Resting Blood Pressure and Heart Rate
Resting Systolic BP Pre- to Post-IHG Training Repeated Measures ANOVA
1a. Resting Systolic BP (Means)
Group
IHG
IHG
Sham
Sham

Time
PrePostPrePost-

Mean
137.94
128.39
142.03
138.79

SE
7.21
7.77
9.31
10.03

N
5
5
3
3

1b. Resting Systolic BP (All Effects)

Resting Diastolic BP Pre- to Post-IHG Training Repeated Measures ANOVA
2a. Resting Diastolic BP (Means)
Group
IHG
IHG
Sham
Sham

Time
PrePostPrePost-

Mean
72.30
73.19
81.91
74.82

SE
4.607
6.033
5.947
7.789

2b. Resting Diastolic BP (All Effects)
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5
3
3
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Resting Mean Arterial BP Pre- to Post-IHG Training Repeated Measures ANOVA
3a. Resting Mean Arterial BP (Means)
Group
IHG
IHG
Sham
Sham

Time
PrePostPrePost-

Mean
91.96
87.94
101.75
95.95

SE
5.084
4.637
6.563
5.987

N
5
5
3
3

3b. Resting Mean Arterial BP (All Effects)

Resting Brachial PP Pre- to Post-IHG Training Repeated Measures ANOVA
4a. Resting Brachial PP (Means)
Group
IHG
IHG
Sham
Sham

Time
PrePostPrePost-

Mean
65.63
60.37
60.12
63.97

SE
6.581
7.479
8.497
9.655

4b. Resting Brachial PP (All Effects)
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N
5
5
3
3
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Effects of IHG Training on Anxiety and Cardiac Output
1a. State Anxiety (IHG Training Group)
State Anxiety Pre- to Post-IHG Training Dependent t-test

Var1 – IHG STAI-S PreVar2 – IHG STAI-S Post-

1b. Trait Anxiety (IHG Training Group)
Trait Anxiety Pre- to Post-IHG Training Dependent t-test

Var3 – IHG STAI-T PreVar4 – IHG STAI-T Post-

142

M.H.K. Thesis – M. Gregory

Windsor – Applied Human Performance

1a. State Anxiety (Sham-trained Group)
State Anxiety Pre- to Post-IHG Training Dependent t-test

Var5 – Sham STAI-S PreVar6 – Sham STAI-S Post-

1b. Trait Anxiety (Sham-trained Group)
Trait Anxiety Pre- to Post-IHG Training Dependent t-test

Var6 – Sham STAI-T PreVar7 – Sham STAI-T Post-
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Resting Average Aortic Root Diameter Pre- to Post- IHG Training Repeated Measures
ANOVA
2a. Resting Average Aortic Root Diameter (Means)
Group
IHG
IHG
Sham
Sham

Time
PrePostPrePost-

Mean
1.944
1.952
1.981
1.945

SE
0.075
0.074
0.097
0.096

N
5
5
3
3

2b. Resting Average Aortic Root Diameter (All Effects)

Resting Supine Heart Rate Pre- to Post- IHG Training Repeated Measures ANOVA
3a. Resting Supine Heart Rate (Means)
Group
IHG
IHG
Sham
Sham

Time
PrePostPrePost-

Mean
60.97
60.64
63.62
64.01

SE
4.468
3.975
5.768
5.132

3b. Resting Supine Heart Rate (All Effects)
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N
5
5
3
3
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Resting Stroke Volume Pre- to Post- IHG Training Repeated Measures ANOVA
4a. Resting Stroke Volume (Means)
Group
IHG
IHG
Sham
Sham

Time
PrePostPrePost-

Mean
75.00
80.03
63.55
66.04

SE
5.415
8.922
6.990
11.518

N
5
5
3
3

4b. Resting Stroke Volume (All Effects)

Resting Cardiac Output Pre- to Post-IHG Training Repeated Measures ANOVA
5a. Resting Cardiac Output (Means)
Group
IHG
IHG
Sham
Sham

Time
PrePostPrePost-

Mean
4.52
4.78
3.99
4.21

SE
0.332
0.494
0.429
0.638

5b. Resting Cardiac Output (All Effects)
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Effects of IHG training on Maximum Voluntary Contraction
Maximum Voluntary Contraction Pre- to Post-IHG Training Repeated Measures ANOVA
1a. Maximum Voluntary Contraction (Means)
Group
IHG
IHG
Sham
Sham

Time
PrePostPrePost-

Mean
58.0
65.8
51.0
59.7

SE
2.817
3.636
5.699
7.357

1b. Maximum Voluntary Contraction (All Effects)
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N
5
5
3
3
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Appendix D: University of Windsor Research Ethics Board Clearance
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Appendix E: McMaster University Research Ethics Board Clearance
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Appendix F: University of Windsor Poster Advertisement
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Post-menopausal women are invited
to participate in a Research Study
Are you a female resident of Windsor who is post-menopausal?
Have you been diagnosed with high blood pressure?
If you answered yes to the previous questions, you may be eligible to
participate in a Research Study. Dr. Cheri McGowan and graduate student
Mike Gregory at the University of Windsor are currently looking for
individuals to participate in a study, approved by the Research Ethics Board,
examining the effects of isometric handgrip exercise on blood pressure.

If you are interested or would like to know more information, please contact
Dr. McGowan
(519)-253-3000 ext. 4979
mcgowanc@uwindsor.ca
Mike Gregory
(519)-253-3000 ext. 2451
gregorym@uwindsor.ca
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Appendix G: McMaster University Poster Advertisement
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Appendix H: University of Windsor Website Advertisement
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Attention all postmenopausal women:
We are looking for participants to take part in a research study at the University of
Windsor, conducted by Drs. Cheri McGowan and Kevin Milne. We are investigating the
effects of isometric handgrip exercise on blood pressure. For more information please
contact Dr. Cheri McGowan at 519-253-3000 ext. 2451 & 4979, or
mcgowanc@uwindsor.ca, and/or study investigator Mike Gregory at 519-253-3000 ext.
2451 or gregorym@uwindsor.ca. This study has been cleared by the University of
Windsor research Ethics Board.
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Appendix I: Windsor Star Newspaper Advertisement

Attention all postmenopausal women:
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We are looking for participants to take part in a research study at the University of
Windsor, conducted by Drs. Cheri McGowan and Kevin Milne. We are investigating the
effects of isometric handgrip exercise on blood pressure. For more information please
contact Dr. Cheri McGowan at 519-253-3000 ext. 2451 & 4979, or
mcgowanc@uwindsor.ca, and/or study investigator Mike Gregory at 519-253-3000 ext.
2451 or gregorym@uwindsor.ca. This study has been cleared by the University of
Windsor research Ethics Board.
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Appendix J: Hamilton Spectator Newspaper Advertisement

Attention all postmenopausal women:
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You may be eligible to participate in a research study at McMaster University, being
conducted by Dr. Maureen MacDonald and graduate student Mike Gregory. We are
investigating the effects of isometric handgrip exercise on blood pressure. For more
information please contact Dr. Maureen MacDonald at 905-525-9140 ext. 27037.
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Appendix K: University of Windsor Consent to Participate in Research Form

CONSENT TO PARTICIPATE IN RESEARCH
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Title of Study: Isometric handgrip training and arterial blood pressure in post-menopausal
women
(University of Windsor site; PROTOCOL 1)
You are asked to participate in a research study conducted by Drs. Cheri McGowan and Kevin
Milne, from the Department of Kinesiology at the University of Windsor.
If you have any questions or concerns about the research, please feel to contact Dr. Cheri
McGowan via telephone (519-253-3000 ext. 2451 or 4979) or email (mcgowanc@uwindsor.ca) or
Dr. Kevin Milne (Telephone: 519-253-3000 ex. 2452; Email: kjmilne@uwindsor.ca). For
questions or concerns during non-working hours, please contact Dr. Cheri McGowan via cell
phone at 734-904-8488.
PURPOSE OF THE STUDY
After menopause, women are at high risk of developing high blood pressure and cardiovascular
disease. This study tests the theory that in post-menopausal women with and without high blood
pressure, a simple form of exercise training, isometric handgrip training, will lower blood
pressure at rest, and during activities of daily life. Our study also tests the theory that this type of
training will improve the ability of the heart to vary its rhythm and quiet the nervous system. In
addition, we expect that certain regulatory substances in the blood (e.g. adrenaline) will be
reduced, as will the tension in the arteries of your neck, and the efficiency of your heart will be
improved.
PROCEDURES
If you volunteer to participate in this study, we would ask you to do the following things:
Inclusion Criteria/Informed Consent/Familiarization Procedures
Visit 1 (30 minutes):
After expressing interest in the study, if you meet the study’s qualifications, you will be invited to
meet the investigators at the Physical Activity and Cardiovascular Research Laboratory (PACR;
Room #240, Human Kinetics Building, University of Windsor). At that time, you will be asked to
read the consent form and information sheet on the study. After meeting with the study
investigators, you will be shown all portions of the investigation. If you are still interested in
participating in the study, you will be asked to sign the consent form. Once you sign the informed
consent, you will fill out a short medical questionnaire, and a physical activity (PARmed-X)
questionnaire which you will take to your health care provider for him or her to complete. We
encourage you to ask any questions related to the study at this time.
Visit 2 (1 hour):
After agreeing to participate in the study, and if you are eligible, you will undergo a practice test
visit. With the exception of the blood draw, we will let you practice all portions of the
investigation (e.g., measurement of blood pressure and heart rate).
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Measurement Procedures- 3rd visit to completion of investigation:
You will undergo the first testing session in the PACR Lab (Room #240, Human Kinetics
Building, University of Windsor). To minimize outside factors on our measures, you will be
asked to not have alcohol and to not exercise vigorously for 24-hours before each testing session.
You will also be asked to avoid caffeine for 12-hours before the tests. All testing will take place at
the same time of day, in a quiet, temperature-controlled room. On testing days, you will be asked
to empty your bladder, as a full bladder can increase blood pressure.
Testing Days 1 and 2 (approximately 0.5 hours): Your resting blood pressure will be measured
in your upper arm after 10 minutes of seated rest. Your blood pressure will be measured 4 times,
with 2-minutes of rest between measures. This will repeated again at least 24-hours after Testing
Day 1.
If you are still eligible to be in the study, the following testing days will occur:
Testing Day 3 (approximately 45 minutes): Twelve hours after your last meal, and after lying
down for 30 minutes, your blood will be taken. Five mL of blood will be collected from a vein in
your arm by a registered practicing nurse. We will use this blood sample to measure blood values
of nervous system activity (“fight or flight” system), oxidative stress (chemical reaction which
can have a negative effect on many cells of the body including the heart and blood vessels), blood
sugar and cholesterol.
Testing Day 4 (approximately 2 hours): Upon arrival at the PACR lab and at least 4 hours
following your last meal, you will complete a self-administered questionnaire (State-Trait anxiety
inventory) in an attempt to control for any possible variability in the cardiovascular testing
measurements performed during this testing session which could occur as a result of your current
emotional state. After which, your resting blood pressure will be measured after 10 minutes of
seated rest, in the same way that is was measured during Testing Days 1 and 2. Your heart rate
will be monitored as well, using 3 sticker-electrodes that will be placed on your chest. Your
breathing frequncy will be measured using a breathing belt placed around your chest.
A technique called microneurography will then be used to measure, just below your knee,
impulses travelling in a nerve to your calf muscle. This procedure has 2 parts. First, the position
of your nerve will be mapped out using a pen-shaped instrument that emits a small electrical
pulse. This will cause the muscles in your lower leg to twitch or tingle. This will be a strange
sensation but will not be painful, and the sensations will disappear when the stimulation stops. A
tiny, sterile wire electrode (about the size of a large human hair) will then be inserted through
your skin and positioned just under the skin about 2-3 centimetres from the nerve site. This will
be followed by the placement of a second tiny electrode, through your skin, into the nerve. The
second electrode will be moved around, until the appropriate recording site is found. The
electrode will remain in the nerve throughout the experiment. In most people, a satisfactory
recording may be obtained after 20-30 minutes, but in some people, a good site cannot be found,
or nerve activity is so low we cannot tell whether the best site has been found. If a good site
cannot be located within 45 minutes, the procedure will stop. Once a proper recording site is
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obtained, your heart rate, blood pressure, breathing rate and nerve impulses will be recorded
continuously for about 10 minutes.
Next, we will measure the pressure of blood flowing through the carotid artery located in your
neck, as well as the diameter of the vessel. While still lying down, a pencil-like probe will be
placed gently against your carotid artery on the right side of your neck and held lightly for a total
of 2 minutes. On the opposite side, an image of the diameter of this same artery will be taken
using an ultrasound wand. We will then use ultrasound to measure the amount of blood pumped
from your heart, by holding a smaller ultrasound wand over your heart and in the notch above
your breast bone.
At the end of the testing session, we will send you home with a device that will record your blood
pressure for the next 24-hours. The morning following, you will return this device to the
Department of Kinesiology’s front office (General Office, Department of Kinesiology, Faculty of
Human Kinetics, University of Windsor).
Following baseline testing, you will be assigned, at random (by chance), to an isometric handgrip
training group or a sham training group. If you are randomized to the isometric handgrip training
group, you will train 3 times per week, for a total of 8-weeks. You will perform 4, 2-minute
squeezes at 30% of your maximum squeeze, using both hands (each separated by 1 minute of rest)
on a computerized handgrip. If you are randomized to the sham training group, you will perform
4, 2-minute squeezes at 3% (instead of 30%) of your maximum squeeze. All training sessions per
week will take place under the supervision of an exercise trainer, where your resting blood
pressure will be measured before each session. Training sessions should not last longer than 30
minutes. Your exercise, nutritional, and medication status (where necessary) will be monitored
throughout the study to make sure they do not change. Your health care provider will also be
informed of the importance of keeping exercise, nutrition and medication status unchanged
throughout the investigation, with the request of notifying one of the study investigators if one or
more of these variables change. At the end of the 8-weeks, all baseline tests will be repeated.
POTENTIAL RISKS AND DISCOMFORTS
You may experience tendonitis in the tendons of the training arms with handgrip training however
this risk is minimal if the exercise is properly performed. The blood pressure and blood flow
measurement procedures are non-invasive but you may experience numbness and/or tingling in
the limb with the cuff(s) while we are taking our measurements. The gel used to image your heart
and/or the sticker-electrodes used to measure your heart rate may cause a skin irritation however,
this risk is minimal.
The insertion of a needle for blood sampling is common practice and involves few risks. There is
local yet transient discomfort with the insertion of the needle, and there is a theoretical risk of
infection, however blood draws will be made under completely sterile conditions. After we take
out this needle, we will press firmly on the skin to minimize bruising.
Microneurography has been shown to be a safe method for measuring sympathetic nerve traffic to
muscle. Microneurography has been used in laboratories all over the world with only 3
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complications in the last 40 years, the worst of which was a slight weakness of the muscle of the
leg lasting 2 to 6 months. You may notice a mild ache in the muscles of the right leg for a few
days after the procedure.
Please contact one of the study investigators if you feel any adverse effects from completing any
portion of the study, and/or if you have any questions or concerns. Exercise leaders and study
investigators will reinforce proper training technique throughout the study intervention period. If
you experience any adverse effects during any testing procedure, first line response will be
provided.
POTENTIAL BENEFITS TO SUBJECTS AND/OR TO SOCIETY
You may or may NOT experience a lower blood pressure at rest or during your activities of daily
life after each part of the study. In addition, you may or may not have improvements in the ability
of your heart to vary its rhythm, a decrease in the activity of your nervous system, reduced tension
in the blood vessels of your neck, an increase in the efficiency of the work of your heart, and/or
reduced oxidative stress.
If we prove our theories, isometric handgrip training may be a possible prevention and/or
treatment option for post-menopausal women, like you.
PAYMENT FOR PARTICIPATION
You will receive a Human Kinetics T-shirt for your participation, and will be reimbursed for
parking costs over the course of the study.
CONFIDENTIALITY
Any information that is obtained in connection with this study and that can be identified with you
will remain confidential and will be disclosed only with your permission.
To ensure your confidentiality, following your consent, you will be assigned an identification
number. Your name will not be mentioned in any publication or presentation, and you will be
identified with only your identification number on all collection tools (electronic or otherwise).
All paper data and all electronic data will be stored in the locked laboratory (PACR Lab, Room
#240, Human Kinetics Building, University of Windsor) of the study investigators. Information
stored on computer will be password-accessible only. With respect to final disposal, all paper
records (including medical and physical activity readiness questionnaires) will be shredded.
PARTICIPATION AND WITHDRAWAL
You can choose whether to be in this study or not. If you volunteer to be in this study, you may
withdraw at any time without consequences of any kind. You may also refuse to answer any
questions you do not wish to answer and still remain in the study. The investigator may withdraw
you from this research if circumstances arise which warrant doing so (e.g., medication, nutrition
and/or physical activity change).
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FEEDBACK OF THE RESULTS OF THIS STUDY TO THE SUBJECTS
You will have the option of receiving results from the study either by mail or email. Results will
also be posted on the University of Windsor’s Research Ethics Board (REB) website
(http://www.uwindsor.ca/reb) at the completion of the study.
SUBSEQUENT USE OF DATA
This data may be used in subsequent studies however your privacy will be upheld with the use of
your unique subject identification number under all circumstances.
RIGHTS OF RESEARCH SUBJECTS
You may withdraw your consent at any time and discontinue participation without penalty. If you
have questions regarding your rights as a research subject, contact: Research Ethics Coordinator,
University of Windsor, Windsor, Ontario, N9B 3P4; Telephone: 519-253-3000, ext. 3948; e-mail:
ethics@uwindsor.ca
SIGNATURE OF RESEARCH SUBJECT/LEGAL REPRESENTATIVE
I understand the information provided for the study Isometric handgrip training and arterial blood
pressure in post-menopausal women – effects and mechanisms (University of Windsor site;
PROTOCOL 1) as described herein. My questions have been answered to my satisfaction, and I
agree to participate in this study. I have been given a copy of this form.
______________________________________
Name of Subject
______________________________________

___________________

Signature of Subject

Date

SIGNATURE OF INVESTIGATOR
These are the terms under which I will conduct research.
_____________________________________

___________________

Signature of Investigator

Date
Revised April 2009
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Appendix L: University of Windsor Letter of Information for Consent to
Participate in Research Form
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LETTER OF INFORMATION FOR CONSENT TO PARTICIPATE IN
RESEARCH
Title of Study: Isometric handgrip training and arterial blood pressure in post-menopausal
women
(University of Windsor site; PROTOCOL 1)
You are asked to participate in a research study conducted by Drs. Cheri McGowan and Kevin
Milne, from the Department of Kinesiology at the University of Windsor.
If you have any questions or concerns about the research, please feel to contact Dr. Cheri
McGowan via telephone (519-253-3000 ext. 2451 or 4979) or email (mcgowanc@uwindsor.ca) or
Dr. Kevin Milne (Telephone: 519-253-3000 ex. 2452; Email: kjmilne@uwindsor.ca). For
questions or concerns during non-working hours, please contact Dr. Cheri McGowan via cell
phone at 734-904-8488.
PURPOSE OF THE STUDY
After menopause, women are at high risk of developing high blood pressure and cardiovascular
disease. This study tests the theory that in post-menopausal women with and without high blood
pressure, a simple form of exercise training, isometric handgrip training, will lower blood
pressure at rest, and during activities of daily life. Our study also tests the theory that this type of
training will improve the ability of the heart to vary its rhythm and quiet the nervous system. In
addition, we expect that certain regulatory substances in the blood (e.g. adrenaline) will be
reduced, as will the tension in the arteries of your neck, and the efficiency of your heart will be
improved.
PROCEDURES
If you volunteer to participate in this study, we would ask you to do the following things:
Inclusion Criteria/Informed Consent/Familiarization Procedures
Visit 1 (30 minutes):
After expressing interest in the study, if you meet the study’s qualifications, you will be invited to
meet the investigators at the Physical Activity and Cardiovascular Research Laboratory (PACR;
Room #240, Human Kinetics Building, University of Windsor). At that time, you will be asked to
read the consent form and information sheet on the study. After meeting with the study
investigators, you will be shown all portions of the investigation. If you are still interested in
participating in the study, you will be asked to sign the consent form. Once you sign the informed
consent, you will fill out a short medical questionnaire, and a physical activity (PARmed-X)
questionnaire which you will take to your health care provider for him or her to complete. We
encourage you to ask any questions related to the study at this time.
Visit 2 (1 hour):
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After agreeing to participate in the study, and if you are eligible, you will undergo a practice test
visit. With the exception of the blood draw, we will let you practice all portions of the
investigation (e.g., measurement of blood pressure and heart rate).
Measurement Procedures- 3rd visit to completion of investigation:
You will undergo the first testing session in the PACR Lab (Room #240, Human Kinetics
Building, University of Windsor). To minimize outside factors on our measures, you will be
asked to not have alcohol and to not exercise vigorously for 24-hours before each testing session.
You will also be asked to avoid caffeine for 12-hours before the tests. All testing will take place at
the same time of day, in a quiet, temperature-controlled room. On testing days, you will be asked
to empty your bladder, as a full bladder can increase blood pressure.
Testing Days 1 and 2 (approximately 0.5 hours): Your resting blood pressure will be measured
in your upper arm after 10 minutes of seated rest. Your blood pressure will be measured 4 times,
with 2-minutes of rest between measures. This will repeated again at least 24-hours after Testing
Day 1.
If you are still eligible to be in the study, the following testing days will occur:
Testing Day 3 (approximately 45 minutes): Twelve hours after your last meal, and after lying
down for 30 minutes, your blood will be taken. Five mL of blood will be collected from a vein in
your arm by a registered practicing nurse. We will use this blood sample to measure blood values
of nervous system activity (“fight or flight” system), oxidative stress (chemical reaction which
can have a negative effect on many cells of the body including the heart and blood vessels), blood
sugar and cholesterol.
Testing Day 4 (approximately 2 hours): Upon arrival at the PACR lab and at least 4 hours
following your last meal, you will complete a self-administered questionnaire (State-Trait anxiety
inventory) in an attempt to control for any possible variability in the cardiovascular testing
measurements performed during this testing session which could occur as a result of your current
emotional state. After which, your resting blood pressure will be measured after 10 minutes of
seated rest, in the same way that is was measured during Testing Days 1 and 2. Your heart rate
will be monitored as well, using 3 sticker-electrodes that will be placed on your chest. Your
breathing frequncy will be measured using a breathing belt placed around your chest.
A technique called microneurography will then be used to measure, just below your knee,
impulses travelling in a nerve to your calf muscle. This procedure has 2 parts. First, the position
of your nerve will be mapped out using a pen-shaped instrument that emits a small electrical
pulse. This will cause the muscles in your lower leg to twitch or tingle. This will be a strange
sensation but will not be painful, and the sensations will disappear when the stimulation stops. A
tiny, sterile wire electrode (about the size of a large human hair) will then be inserted through
your skin and positioned just under the skin about 2-3 centimetres from the nerve site. This will
be followed by the placement of a second tiny electrode, through your skin, into the nerve. The
second electrode will be moved around, until the appropriate recording site is found. The
electrode will remain in the nerve throughout the experiment. In most people, a satisfactory
recording may be obtained after 20-30 minutes, but in some people, a good site cannot be found,
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or nerve activity is so low we cannot tell whether the best site has been found. If a good site
cannot be located within 45 minutes, the procedure will stop. Once a proper recording site is
obtained, your heart rate, blood pressure, breathing rate and nerve impulses will be recorded
continuously for about 10 minutes.
Next, we will measure the pressure of blood flowing through the carotid artery located in your
neck, as well as the diameter of the vessel. While still lying down, a pencil-like probe will be
placed gently against your carotid artery on the right side of your neck and held lightly for a total
of 2 minutes. On the opposite side, an image of the diameter of this same artery will be taken
using an ultrasound wand. We will then use ultrasound to measure the amount of blood pumped
from your heart, by holding a smaller ultrasound wand over your heart and in the notch above
your breast bone.
At the end of the testing session, we will send you home with a device that will record your blood
pressure for the next 24-hours. The morning following, you will return this device to the
Department of Kinesiology’s front office (General Office, Department of Kinesiology, Faculty of
Human Kinetics, University of Windsor).
Following baseline testing, you will be assigned, at random (by chance), to an isometric handgrip
training group or a sham training group. If you are randomized to the isometric handgrip training
group, you will train 3 times per week, for a total of 8-weeks. You will perform 4, 2-minute
squeezes at 30% of your maximum squeeze, using both hands (each separated by 1 minute of rest)
on a computerized handgrip. If you are randomized to the sham training group, you will perform
4, 2-minute squeezes at 3% (instead of 30%) of your maximum squeeze. All training sessions per
week will take place under the supervision of an exercise trainer, where your resting blood
pressure will be measured before each session. Training sessions should not last longer than 30
minutes. Your exercise, nutritional, and medication status (where necessary) will be monitored
throughout the study to make sure they do not change. Your health care provider will also be
informed of the importance of keeping exercise, nutrition and medication status unchanged
throughout the investigation, with the request of notifying one of the study investigators if one or
more of these variables change. At the end of the 8-weeks, all baseline tests will be repeated.
POTENTIAL RISKS AND DISCOMFORTS
You may experience tendonitis in the tendons of the training arms with handgrip training however
this risk is minimal if the exercise is properly performed. The blood pressure and blood flow
measurement procedures are non-invasive but you may experience numbness and/or tingling in
the limb with the cuff(s) while we are taking our measurements. The gel used to image your heart
and/or the sticker-electrodes used to measure your heart rate may cause a skin irritation however,
this risk is minimal.
The insertion of a needle for blood sampling is common practice and involves few risks. There is
local yet transient discomfort with the insertion of the needle, and there is a theoretical risk of
infection, however blood draws will be made under completely sterile conditions. After we take
out this needle, we will press firmly on the skin to minimize bruising.

170

M.H.K. Thesis – M. Gregory

Windsor – Applied Human Performance

Microneurography has been shown to be a safe method for measuring sympathetic nerve traffic to
muscle. Microneurography has been used in laboratories all over the world with only 3
complications in the last 40 years, the worst of which was a slight weakness of the muscle of the
leg lasting 2 to 6 months. You may notice a mild ache in the muscles of the right leg for a few
days after the procedure.
Please contact one of the study investigators if you feel any adverse effects from completing any
portion of the study, and/or if you have any questions or concerns. Exercise leaders and study
investigators will reinforce proper training technique throughout the study intervention period. If
you experience any adverse effects during any testing procedure, first line response will be
provided.
POTENTIAL BENEFITS TO SUBJECTS AND/OR TO SOCIETY
You may or may NOT experience a lower blood pressure at rest or during your activities of daily
life after each part of the study. In addition, you may or may not have improvements in the ability
of your heart to vary its rhythm, a decrease in the activity of your nervous system, reduced tension
in the blood vessels of your neck, an increase in the efficiency of the work of your heart, and/or
reduced oxidative stress.
If we prove our theories, isometric handgrip training may be a possible prevention and/or
treatment option for post-menopausal women, like you.
PAYMENT FOR PARTICIPATION
You will receive a Human Kinetics T-shirt for your participation, and will be reimbursed for
parking costs over the course of the study.
CONFIDENTIALITY
Any information that is obtained in connection with this study and that can be identified with you
will remain confidential and will be disclosed only with your permission.
To ensure your confidentiality, following your consent, you will be assigned an identification
number. Your name will not be mentioned in any publication or presentation, and you will be
identified with only your identification number on all collection tools (electronic or otherwise).
All paper data and all electronic data will be stored in the locked laboratory (PACR Lab, Room
#240, Human Kinetics Building, University of Windsor) of the study investigators. Information
stored on computer will be password-accessible only. With respect to final disposal, all paper
records (including medical and physical activity readiness questionnaires) will be shredded.
PARTICIPATION AND WITHDRAWAL
You can choose whether to be in this study or not. If you volunteer to be in this study, you may
withdraw at any time without consequences of any kind. You may also refuse to answer any
questions you do not wish to answer and still remain in the study. The investigator may withdraw
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you from this research if circumstances arise which warrant doing so (e.g., medication, nutrition
and/or physical activity change).
FEEDBACK OF THE RESULTS OF THIS STUDY TO THE SUBJECTS
You will have the option of receiving results from the study either by mail or email. Results will
also be posted on the University of Windsor’s Research Ethics Board (REB) website
(http://www.uwindsor.ca/reb) at the completion of the study.
SUBSEQUENT USE OF DATA
This data may be used in subsequent studies however your privacy will be upheld with the use of
your unique subject identification number under all circumstances.
RIGHTS OF RESEARCH SUBJECTS
You may withdraw your consent at any time and discontinue participation without penalty. If you
have questions regarding your rights as a research subject, contact: Research Ethics Coordinator,
University of Windsor, Windsor, Ontario, N9B 3P4; Telephone: 519-253-3000, ext. 3948; e-mail:
ethics@uwindsor.ca

SIGNATURE OF INVESTIGATOR
These are the terms under which I will conduct research.
_____________________________________

___________________

Signature of Investigator

Date
Revised April 2009
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Appendix M: McMaster University Consent Form

LETTER OF INFORMATION / CONSENT
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A Study investigating the effects of isometric handgrip training on arterial blood
pressure in post-menopausal women
Investigators: Michael Gregory, MHK Candidate; Dr. Maureen MacDonald, PhD;
Dr. Cheri McGowan, PhD; Dr. Kevin Milne, PhD
Principal Investigator

:

Student Investigator:

Michael Gregory
Department of Kinesiology
University of Windsor
Windsor, Ontario, Canada
(519) 253-3000 ext. 2541
E-mail: (gregorym@uwindsor.ca)
Co-Investigator(s):
Dr. Cheri McGowan
Department of Kinesiology
University of Windsor
Windsor, Ontario, Canada
(519) 253-3000 ext. 2451
Email: (mcgowanc@uwindsor.ca)

Faculty Supervisor:
Dr. Maureen MacDonald
Department of Kinesiology
McMaster University
Hamilton, Ontario, Canada
(905) 525-9140 ext. 23580
Email: (macdonmj@mcmaster.ca)

Dr. Kevin Milne
Department of Kinesiology
University of Windsor
Windsor, Ontario, Canada
(519) 253-3000 ext. 2452
Email: (kjmilne@uwindsor.ca)
Research Sponsor: Canadian Institutes of Health Research – University of Windsor (TriSuccess Grant #: ORS-ERSO 29381)
Purpose of the Study
After menopause, women are at high risk of developing high blood pressure and heart
disease. This study tests the theory that in post-menopausal women with and without high
blood pressure, a simple form of exercise training, isometric handgrip training, will lower
blood pressure at rest and during activities of daily life. Our study also tests the theory
that this type of training will quiet the nervous system. In addition, we expect that the
tension in the arteries of your neck, and/or the efficiency of your heart will be improved.
Procedures involved in the Research
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If you volunteer to participate in this study, we would ask you to do the following things:
Inclusion Criteria/Informed Consent/Familiarization Procedures
Visit 1 (30 minutes):
After expressing interest in the study, if you meet the study’s qualifications, you will be
invited to meet the investigators at the Cardiovascular and Dynamics Laboratory (Room
#E102, Ivor Wynne Centre, McMaster University). At that time, you will be asked to
read the consent form and information sheet on the study. After meeting with the study
investigators, you will be shown all portions of the investigation. If you are still interested
in participating in the study, you will be asked to sign the consent form. Once you sign
the informed consent, you will fill out a short medical questionnaire, and a physical
activity (PARmed-X) questionnaire which you will take to your health care provider for
him or her to complete. We encourage you to ask any questions related to the study at this
time.
Visit 2 (1 hour):
After agreeing to participate in the study, and if you are eligible, you will undergo a
practice test visit. We will let you practice all portions of the investigation (e.g.,
measurement of blood pressure and heart rate).
Measurement Procedures - 3rd visit to completion of investigation:
You will undergo the first testing session in the Cardiovascular and Dynamics Lab (Room
#E102, Ivor Wynne Centre, McMaster University). To minimize outside factors on our
measures, you will be asked to not have alcohol and to not exercise vigorously for 24hours
before
each
testing session. You will also be asked to avoid caffeine for 12-hours before the tests. All
testing will take place at the same time of day, in a quiet, temperature-controlled room.
On testing days, you will be asked to empty your bladder as a full bladder can increase
blood pressure.
Testing Days 1 and 2 (approximately 0.5 hours): Your resting blood pressure will be
measured in your upper arm after 10 minutes of seated rest. Your blood pressure will be
measured 4 times, with 2-minutes of rest between measures. This will repeated again at
least 24-hours after Testing Day 1.
If you are still eligible to be in the study, the following testing days will occur:
Testing Day 3 (approximately 2 hours): Upon arrival at the lab, your resting blood
pressure will be measured after 10 minutes of seated rest, in the same way that is was
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measured during Testing Days 1 and 2. Your heart rate will be monitored as well, using 3
sticker-electrodes that will be placed on your chest. Your breathing frequncy will be
measured using a breathing belt placed around your chest.
A technique called microneurography will then be used to measure, just below your knee,
impulses travelling in a nerve to your calf muscle. This procedure has 2 parts. First, the
position of your nerve will be mapped out using a pen-shaped instrument that emits a
small electrical pulse. This will cause the muscles in your lower leg to twitch or tingle.
This will be a strange sensation but will not be painful, and the sensations will disappear
when the stimulation stops. A tiny, sterile wire electrode (about the size of a large human
hair) will then be inserted through your skin and positioned just under the skin about 2-3
centimetres from the nerve site. This will be followed by the placement of a second tiny
electrode, through your skin, into the nerve. The second electrode will be moved around,
until the appropriate recording site is found. The electrode will remain in the nerve
throughout the experiment. In most people, a satisfactory recording may be obtained after
20-30 minutes, but in some people, a good site cannot be found, or nerve activity is so
low we cannot tell whether the best site has been found. If a good site cannot be located
within 45 minutes, the procedure will stop. Once a proper recording site is obtained, your
heart rate, blood pressure, breathing rate and nerve impulses will be recorded
continuously for about 10 minutes. This technique will only be performed by a trained
and actively practicing microneurographer (Dr. Phil Millar, McMaster).
Next, we will measure the pressure of blood flowing through the carotid artery located in
your neck, as well as the diameter of the vessel. While still lying down, a pencil-like
probe will be placed gently against your carotid artery on the right side of your neck and
held lightly for a total of 2 minutes. On the opposite side, an image of the diameter of this
same artery will be taken using an ultrasound wand. We will then use ultrasound to
measure
the
amount
of
blood
pumped from your heart, by holding a smaller ultrasound wand over your heart and in the
notch above your breast bone.
At the end of the testing session, we will send you home with a device that will record
your blood pressure for the next 24 hours. The morning following, you will return this
device to the lab (Cardiovascular and Dynamics Lab, Room #E102, Ivor Wynne Centre,
McMaster University).
Following baseline testing, you will be assigned, at random (by chance), to an isometric
handgrip training group or a sham training group. If you are randomized to the isometric
handgrip training group, you will train 3 times per week, for a total of 8 weeks. You will
perform 4, 2-minute squeezes at 30% of your maximum squeeze, using both hands (each
separated by 1 minute of rest) on a computerized handgrip. If you are randomized to the
sham training group, you will perform 4, 2-minute squeezes at 3% (instead of 30%) of
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your maximum squeeze. All training sessions per week will take place under the
supervision of an exercise trainer, where your resting blood pressure will be measured
before each session. Training sessions should not last longer than 30 minutes. Your
exercise, nutritional, and medication status (where necessary) will be monitored
throughout the study to make sure they do not change. Your health care provider will also
be informed of the importance of keeping exercise, nutrition and medication status
unchanged throughout the investigation, with the request of notifying one of the study
investigators if one or more of these variables change.
At the end of the 8-weeks, all baseline tests will be repeated.
Potential Harms, Risks or Discomforts:
You may experience tendonitis in the tendons of the training arms with handgrip training
however this risk is minimal if the exercise is properly performed. The blood pressure and
blood flow measurement procedures are non-invasive but you may experience numbness
and/or tingling in the limb with the cuff(s) while we are taking our measurements. The gel
used to image your heart and/or the sticker-electrodes used to measure your heart rate
may cause a skin irritation however, this risk is minimal.
Microneurography has been shown to be a safe method for measuring sympathetic nerve
traffic to muscle. Microneurography has been used in laboratories all over the world with
only 3 complications in the last 40 years, the worst of which was a slight weakness of the
muscle of the leg lasting 2 to 6 months. You may notice a mild ache in the muscles of the
right leg for a few days after the procedure. As this technique involves the insertion of a
small electrode through the skin, there is a theoretical risk of infection at the site
involved; however, the site is sterilized with the use of iodine and alcohol (99%) prior to
the insertion and following the
removal of the electrode from the location. Furthermore, the electrodes are all
individually packaged and sterilized through the use of an autoclave as well, and no
electrodes are ever recycled or reused.
Please contact one of the study investigators if you feel any adverse effects from
completing any portion of the study, and/or if you have any questions or concerns.
Exercise leaders and study investigators will reinforce proper training technique
throughout the study intervention period. If you experience any adverse effects during
any testing procedure, first line response will be provided.
Potential Benefits
You may or may NOT experience a lower blood pressure at rest or during your activities
of daily life after each part of the study. In addition, you may or may not have a decrease
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in the activity of your nervous system, reduced tension of the blood vessels of your neck,
and/or an increase in the efficiency of the work of your heart.
If we prove our theories, isometric handgrip training may be a possible prevention and/or
treatment option for high blood pressure in post-menopausal women, like you.
Payment or Reimbursement
All parking costs will be reimbursed, (excluding parking violations).
Confidentiality
Any information that is obtained in connection with this study and that can be identified
with you will remain confidential and will be disclosed only with your permission.
To ensure your confidentiality, following your consent, you will be assigned an
identification number. Your name will not be mentioned in any publication or
presentation, and you will be identified with only your identification number on all
collection tools (electronic or otherwise). All paper data and all electronic data will be
stored in the locked laboratory Cardiovascular and Dynamics Laboratory – Room #E102,
Ivor Wynne Centre, McMaster University) of the study investigators. Information stored
on computer will be password-accessible only. With respect to final disposal, all paper
records (including medical and physical activity readiness questionnaires) will be
shredded and all electronic data will be erased (formatted).
Participation and Withdrawal
You can choose whether to be in this study or not. If you volunteer to be in this study,
you may withdraw at any time without consequences of any kind. You may also refuse to
answer any questions you do not wish to answer and still remain in the study. The
investigator may withdraw you from this research if circumstances arise which warrant
doing so (e.g., medication, nutrition and/or physical activity change).
Information about the Study Results
If you would like to receive the summary personally, please let me know how you would
like me to send it to you. This data may be used in subsequent studies however your
privacy will be upheld with the use of your unique subject identification number under all
circumstances.
Questions about the Study
If you have questions or need more information about the study itself, please contact: Dr.
Maureen MacDonald: macdonmj@mcmaster.ca, 905-525-9140 ext. 23580 and/or
Michael Gregory: gregorym@uwindsor.ca, 905-525-9140 ext. 27037.
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This study has been reviewed by the Hamilton Health Sciences/Faculty of Health
Sciences Research Ethics Board and has received ethics clearance.
If you have concerns or questions about your rights as a participant or about the way the
study is conducted, please contact the Office of the Chair of the HHS/FHS REB at 905521-2100, Ext. 42013.
CONSENT
I have read the information presented in the information letter about a study being
conducted by the LPI, Dr. Maureen MacDonald of McMaster University, Master’s
student Michael Gregory, and co-investigators Drs. Cheri McGowan and Kevin Milne, of
the University of Windsor.
I have had the opportunity to ask questions about my involvement in this study and to
receive additional details I requested.
I understand that if I agree to participate in this study, I may withdraw from the study at
any time. I have been given a copy of this form. I agree to participate in the study.
Signature: ______________________________________
Name of Participant (Printed) ___________________________________
Date: __________________________________
Name of Investigator (Printed): ___________________________________
Signature: ______________________________________
Date: __________________________________
1. …Yes, I would like to receive a summary of the study’s results.
Please send them to this email address
__________________________________________
or to this mailing address:
________________________________________________

_________________________________________________
… No, I do not want to receive a summary of the study’s results.
3. I agree to be contacted about a follow-up interview, and understand that I can always
decline the request.
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... Yes. Please contact me at: ____________________________________________
... No.
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Appendix N: Medical Questionnaire

Last Name__________________________________ First Name _________________________________________
Address___________________________________________ City_________ Province_______________________
Sex (please circle): M F
Height: ___________________ Weight:_______________________
Date of Birth ______________________Home Phone # (
)______________ Postal Code_______________
Month

Year

FOR EMERGENCY NOTIFY: Name______________________________ Relationship_______________________
Address_____________________________________________________
Phone____________________________
Family Doctor's Name______________________________________
Date of Last Physical________________
Please Check Yes or No:

Yes No
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Have you ever been hospitalized?................................................................................................................□
If yes, please specify?

□

_______________________________________________________________________________________

Have you ever had surgery? ........................................................................................................................□
If yes, please specify?

□

_______________________________________________________________________________________

2.

Are you presently taking any medications or pills? ....................................................................................□
If yes, please specify?

□

_______________________________________________________________________________________

Are you presently taking any vitamins or supplements? ............................................................................□

3.

□
Do you have any allergies (medicine, bees or other stinging insects) ................................................... ....□ □
If yes, please specify?

__________________________________________________________________________________________

4.

Have you ever passed out during or after exercise? ...................................................................................□

□
Have you ever been dizzy during or after exercise? ..................................................................................□ □
Have you ever had chest pain during or after exercise? ............................................................................□ □
Do you have high blood pressure? .............................................................................................................□ □

If yes, are you being treated for this condition?__________________________________________________________________
Have you ever been told that you have a heart murmer? ..........................................................................□
Have you ever had racing of your heart or skipped heartbeats? ................................................................□
Has anyone in your family died of heart problems or a sudden death before age 50? ..............................□
5.

Do you have any skin problems (itching, rashes, acne) .............................................................................□

6.

Do you have Diabetes?................................................................................................................................□

7.

Do you have Asthma?.................................................................................................................................□

8.

Do you have any type of cardiovascular disease? .....................................................................................□
If yes, please specify?

□
□
□
□
□
□
□

__________________________________________________________________________________________

9.

Have you had any other medical problems (infectious mononucleosis, etc.)? ..........................................□

10. Have you had any medical problems since your last physical? .................................................................□
11. Have you had any unexplained weight change?..........................................................................................□
12. Do you smoke?............................................................................................................................................□
13. Are you postmenopausal?............................................................................................................................□
If yes, please specify?_______________________________________________________________
Please explain any physical limitations that may prevent you from completing this study:
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Appendix O: Physical Activity Readiness Medical Examination Questionnaire
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Appendix P: University of Windsor Health Care Provider Documents
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Date: __________________.
Dear Dr. __________________,

Your patient, ___________________________________, has expressed interest in
participating in our research study in the Department of Kinesiology at the University of
Windsor entitled: Isometric handgrip training and arterial blood pressure in postmenopausal women (see attached Letter of Information for Consent for details). If you
approve your patient’s participation in our study (via Parmed-X), we kindly request that
you or a representative inform us of any changes in medically-endorsed exercise,
nutrition or medication status, as these changes may influence our findings. We ask that
you sign the attached form for return with the PARmed-X to acknowledge receipt of this
request.
Thank-you for your help, and we appreciate your support. Please do not hesitate to
contact us if you have any questions or concerns.
Sincerely,

Drs. Cheri McGowan and Kevin Milne
Assistant Professors
Department of Kinesiology
Faculty of Human Kinetics
University of Windsor
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Date: __________________.

Dear Drs. McGowan and Milne,
I, ___________________________________, acknowledge that my patient
____________________has expressed interest in participating in our research study in
the Department of Kinesiology at the University of Windsor entitled: Isometric handgrip
training and arterial blood pressure in post-menopausal women. I have approved my
patient’s participation in your study (via Parmed-X), and I, or one of my representatives,
will inform you of any changes in medically-endorsed exercise, nutrition or medication
status.

_______________________
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Appendix Q: McMaster University Health Care Provider Documents
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Date: __________________.
Dear Dr. __________________,
Your patient, ___________________________________, has expressed interest
in participating in our research study in the Department of Kinesiology at
McMaster University, entitled: Isometric handgrip training and arterial blood
pressure in post-menopausal women (see attached Letter of Information for
Consent for details). If you approve your patient’s participation in our study (via
Parmed-X), we kindly request that you or a representative inform us of any
changes in medically-endorsed exercise, nutrition or medication status, as these
changes may influence our findings. We ask that you sign the attached form for
return with the PARmed-X to acknowledge receipt of this request.
Thank-you for your help, and we appreciate your support. Please do not hesitate
to contact us if you have any questions or concerns.
Sincerely,
Dr. Maureen MacDonald
Professor
Department of Kinesiology
Faculty of Human Kinetics
McMaster University
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Date: __________________.

Dear Dr. MacDonald,
I, ___________________________________, acknowledge that my patient
____________________has expressed interest in participating in our research
study in the Department of Kinesiology at McMaster University entitled: Isometric
handgrip training and arterial blood pressure in post-menopausal women. I have
approved my patient’s participation in your study (via Parmed-X), and I, or one of
my representatives, will inform you of any changes in medically-endorsed
exercise, nutrition or medication status.

____________________________________
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Appendix R: Training Log
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TRAINING LOG:
Participant ID: _______________________________________________

Date

What was your
maximum
voluntary
contraction
value?
Rightmax &
Leftmax

Did you
complete two
sets with
each hand?
(% at end of
session)

Have you had any
new medications
prescribed to you
and/or have you
started taking any
new products?

Have you
had any
significant
dietary
changes? if
yes, please
describe.

Have you had
any physical
activity
changes? If
yes, please
describe.

Please Note:
- A change in diet is any abnormal addition or subtraction of calories or foods
- A change in medication is any addition or subtraction of medications (i.e. change)
- A change in physical activity is the addition or subtraction of a structured physical activity program
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Appendix S: University of Windsor PACR Lab Emergency Action Plan

EMERGENCY ACTION PLAN (EAP)
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FOR MEDICAL EMERGENCIES DURING EXERCISE TESTING

STEP 1:

REMAIN CALM.
CONTROL and ASSESS the situation.
DESIGNATE a person to CALL and meet EMERGENCY PERSONNEL:

Campus Police EXT. 4444

OR

911

(they will dispatch required authorities)

OUR ADDRESS/DIRECTIONS:
The University of Windsor
Human Kinetics Building
2555 College Ave.
Main Entrance off College Ave.

Room# 240 (uppermost floor)
Go in through the main doors of the Human

STEP 2:

PERFORM all measures (CPR/First Aid) to ensure safety of subject.
ATTEND to subject until replaced by emergency personnel.
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Appendix T: McMaster University Vascular Dynamics Lab Emergency Action Plan
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Vita Auctoris
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Richard and Jean Gregory. Mike graduated from John McGregor Secondary School in
2004. Following high school, Mike completed a Bachelor of Science degree at the
University of Guelph in 2009. Following his undergraduate studies, Mike earned a
Master’s of Human Kinetics degree at the University of Windsor in 2012. Mike plans to
pursue a PhD in Health and Rehabilitation Sciences at Western University in fall 2012.
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